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C LINICAL trials to evaluate efficacy or effectiveness of analgesics pose ethical and scientific challenges 
for all ages, but especially for children. For sound scien-
tific reasons, the standard approach to adult acute pain tri-
als involves enrollment of patients with moderate to severe 
pain, randomization between active drug and placebo, and 
comparison of pain scores over time between active and pla-
cebo subjects as the primary measure of analgesic efficacy 
(fig. 1A).1 The ethical basis of this approach rests on adults 
making informed decisions to bear the risk of assignment 
to a placebo group and potentially to experience continued 
pain during the study period. Comparative effectiveness tri-
als involving no placebo group are relevant for guiding clini-
cal decision-making, but they pose statistical problems for 
establishing drug efficacy.2
For children, as vulnerable subjects, there is greater ethi-
cal concern about a significant risk of unrelieved pain in 
clinical trials, particularly where there are existing effective 
treatments. For ethical and practical reasons, pediatric anal-
gesic trials have proceeded slowly. The U.S. Congress, the 
Food and Drug Administration, and the European Union 
have generated incentives for pharmaceutical companies to 
test analgesics in children, and some funding mechanisms 
via the Food and Drug Administration and the National 
Institutes of Health have supported a small number of inves-
tigator-initiated pediatric trials for off-patent analgesics that 
lack commercial incentives.3 Despite these initiatives, enroll-
ment rates in pediatric analgesic trials have been very low.4
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Background: Designing analgesic clinical trials in pediatrics requires a balance between scientific, ethical, and practical con-
cerns. A previous consensus group recommended immediate rescue designs using opioid sparing as a surrogate measure of 
analgesic efficacy. The authors summarize the performance of rescue analgesic designs in pediatric trials of four commonly 
used classes of analgesics: opioids, nonsteroidal antiinflammatory drugs, acetaminophen, and local anesthetics.
Methods: MEDLINE, Embase, CINAHL, The Cochrane Library, and Web of science were searched in April 2013. The 85 
studies selected were randomized or controlled clinical trials using immediate rescue paradigms in postoperative pain settings. 
A random-effects meta-analysis was used to synthesize predefined outcomes using Hedges’ g. Difference between the means of 
the treatment arms were also expressed as a percentage of the corresponding value in the placebo group (placebo-treatment/
placebo). Distributions of pain scores in study and control groups and relationships between opioid sparing and pain scores 
were examined.
Results: For each of the four study drug classes, significant opioid sparing was demonstrated in a majority of studies by one 
or more of the following endpoints: (1) total dose (milligram per kilogram per hour), (2) percentage of children requiring 
rescue medication, and (3) time to first rescue medication (minutes). Pain scores averaged 2.4/10 in study groups, 3.4/10 in 
control groups.
Conclusions: Opioid sparing is a feasible pragmatic endpoint for pediatric pain analgesic trials. This review serves to guide 
future research in pediatric analgesia trials, which could test whether some specific design features may improve assay sensitiv-
ity while minimizing the risk of unrelieved pain. (Anesthesiology 2015; 122:150-71)
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What We Already Know about This Topic
•	 Traditional approaches to pediatric analgesic trials may leave 
patients with insufficiently treated pain
•	 Whether rescue treatments are generally effective in pediatric 
analgesia trials remains unclear
What This Article Tells Us That Is New
•	 The investigators performed a meta-analysis of pediatric trials 
with four classes of analgesics, using rescue/opioid sparing 
designs
•	 Average pain scores were low and similar in control and ex-
perimental analgesic groups, confirming the ethical basis of 
opioid-sparing rescue designs
•	 Opioid-sparing designs also showed good assay sensitivity
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In November 2010, an expert consensus group was con-
vened by the Anesthetic, Analgesic and Addiction Drugs 
section of the Food and Drug Administration to address 
pediatric analgesic trial design issues. Recommendations 
from this group were published in Pediatrics in 2012.1 One 
prominent recommendation was to regard rescue-analgesic 
sparing as a pragmatic surrogate primary endpoint in pediat-
ric analgesic trials. In order to maintain the scientific advan-
tages of the traditional adult design, subjects could still be 
blinded and randomized between study drug and placebo. 
By providing immediate access to incremental rescue anal-
gesia, especially via patient-controlled analgesia (PCA) or 
nurse-controlled analgesia (NCA) pumps, we expected that 
these designs would reduce the odds that subjects, especially 
those randomized to placebo, would experience unrelieved 
severe pain (fig. 1, B and C). This recommendation was 
based on committee members’ opinions and informal review 
of a small number of successful trials, but not on any system-
atic review or quantitative analysis.
With this background, we now attempt a systemic review 
and quantitative analysis of rescue analgesic designs in pedi-
atric trials of four commonly used classes of analgesics for 
acute pain: opioids, nonsteroidal antiinflammatory drugs 
(NSAIDs), acetaminophen, and local anesthetics. Our 
hypotheses were (1) immediate opioid rescue designs provide 
reasonable assay sensitivity as pragmatic surrogate measures of 
analgesia efficacy, (2) surrogate efficacy effect sizes vary with 
drug class and study design, choice of opioid-sparing end-
points, method of rescue analgesic administration, and type 
of surgery, and (3) subjects randomized to either study drug 
or control/placebo groups with these designs had acceptably 
low mean pain scores (additional technical aspects and details 
relevant to researchers in the field can be found in Supple-
mental Digital Content 1, http://links.lww.com/ALN/B91).
Materials and Methods
The search strategy is described in detail in Section A1 of 
Supplemental Digital Content 1, http://links.lww.com/
ALN/B91.
Selection Criteria
Studies were included if they met the following criteria: (1) 
randomized or controlled clinical trial; (2) children and ado-
lescents aged ≤18 yr; (3) use of immediate rescue paradigms; 
and (4) assessed rescue medication and/or pain scores in 
postoperative pain setting.
For the purpose of this study, we included articles only 
if they (1) included placebo or control groups; (2) used IV 
opioids as rescue medication; and (3) used opioids, NSAIDs, 
acetaminophen, or local anesthetics as the “study drug,” which 
was tested for efficacy against a placebo or other control.
We chose to evaluate the following three analgesic sparing 
outcomes: (1) rescue opioid usage (milligram per kilogram 
per hour), (2) percentage of subjects requiring rescue medi-
cation, or (3) time to first rescue medication (minutes). No 
language restrictions were applied. In calculating rescue opi-
oid usage, opioids were converted to morphine equivalents.* 
In assessing the hourly usage, we chose the shortest reported 
timeframe over an hour and divided the morphine equiva-
lent by this timeframe. For articles reporting pain scores, we 
standardized all the pain scores to a 0 to 10 scale.5,6
Data Synthesis and Statistical Analysis
Data were extracted independently by two reviewers (J.K. 
and C.D.). Inconsistencies were resolved in consensus meet-
ings. Additional study variables were extracted and tabu-
lated, including age range of patients; sample sizes; type(s) 
of surgery; dose regimes for study drugs and rescue opioid, 
method of pain assessment; criteria for opioid administra-
tion; and duration of follow-up. Each included study was 
graded for quality and scored using the Jadad criteria.7
Two methods of assessing opioid sparing were used. First, 
we used a meta-analytic approach. We estimated Hedges’ g 
and the 95% CI between the study drug and control groups.8 
Data management and calculations were performed using 
Comprehensive Meta-Analysis, version 2.0.† Since consider-
able heterogeneity was expected, all analyses were performed 
with a random-effects model.9 We assessed the presence of 
publication bias using the fail-safe N method.10 To assess 
Fig. 1. (A) Typical time course of pain scores for a double-
blind, parallel-group, placebo-controlled, active comparator 
analgesic trial. Note that in general, requirement for rescue 
analgesia results in termination of pain scoring for that sub-
ject. (B) Idealized time course of hourly rescue dosing of a 
short-acting opioid. (C) Idealized time course of the pain. 
Note that, depending on the dosing schedule for rescue anal-
gesics, in some trials of this design, pain scores remain lower 
in the active group than in the placebo group. VAS = visual 
analog scale. Reproduced, with permission, from Berde et al. 
Pediatrics 2012; 129:354–64.1
* Available at: www.globalrph.com/narcoticonv.htm. Accessed June 
27, 2014.
† Available at: www.meta-analysis.com. Accessed June 27, 2014.
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heterogeneity between studies, Q-statistics were calculated. A 
statistically significant Q indicates a heterogeneous distribu-
tion of odds ratios between studies, meaning that systematic 
differences, possibly influencing the results, are present.11 In 
addition, the degree of inconsistency was quantified by the 
I 2 statistic, which measures the percentage of variation across 
studies that is due to heterogeneity rather than chance.12 A 
0% value means no heterogeneity, and higher values repre-
sent an increase in heterogeneity. Generally, heterogeneity is 
categorized at 25% (low), 50% (moderate), and 75% (high). 
Given the large number of possible factors influencing the 
standardized effect size, we chose not to conduct any sensitiv-
ity analyses to explain the heterogeneity, except for subgroup 
analyses with regard to type of surgery to assess its influence 
on assay sensitivity and choice of outcome.
Second, mean opioid sparing by the study drug was 
expressed as percent of maximum possible effect (placebo – 
study/placebo),13 as in pharmacologic studies.14
A third approach to data synthesis explored the distribu-
tion of pain scores in subjects randomized to study drug or 
control conditions. A “perfect rescue paradigm” should in 
theory result in low and nearly equal pain scores in both 
active and placebo groups (fig. 1C).1 We wanted to evaluate 
the degree to which this aim is achieved in practice and to 
depict this balance between assay sensitivity and potential 
for unrelieved pain in control subjects. To do this we plot-
ted each of these opioid-sparing endpoints against the mean 
pain scores for subjects in the control/placebo group. We 
refer to the relationship between these opioid-sparing end-
points and the pain in the controls as the “efficacy–burden 
relationship” for each study. This relationship is meant to 
assess both how well a study performed in terms of effect size 
(opioid sparing between test drug and control groups) and 
how severe the pain was in the group that was randomized 
not to receive the test drug.
Fig. 2. Flow chart of literature search with summary of excluded and included studies. IM = intramuscular; LA = local anesthetic; 
NSAIDs = nonsteroidal antiinflammatory drugs.
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Results
Study Selection
The study selection procedure is summarized in figure 2. 
The summary of characteristics of the studies is shown in 
table 1.15–98 All included studies were controlled blinded tri-
als with quality scores of 3 to 5 on the Jadad scale.7 Selected 
results of publication bias and tests of heterogeneity, as well 
as efficacy measures of the individual studies and the graphi-
cal representation of the efficacy–burden relationship are 
presented in tables 2 and 3 in Section A3 of Supplemental 
Digital Content 1, http://links.lww.com/ALN/B91.
Opioids as the Study Drug 
Details of the 33 included articles (48 active study drug 
arms) can be seen in Section A2 of Supplemental Digital 
Content 1, http://links.lww.com/ALN/B91. Two special 
cases are noteworthy. Trials using intrathecal or epidural opi-
oids as the study drug gave the largest effect sizes and high-
est efficacy to burden relationships. Intrathecal and epidural 
opioids, especially morphine and hydromorphone, have 
markedly higher potency and duration of action compared 
to the same opioids given systemically. Conversely, when the 
ultra–short-acting opioid remifentanil31 was given intraoper-
atively as study drug, it produced a significant negative post-
operative opioid-sparing effect, that is, greater opioid use in 
patients receiving study drug versus placebo, consistent with 
previous animal and adult human studies showing remifent-
anil’s potential to induce hyperalgesia and acute tolerance.99
Total Opioid Usage (Milligram per Kilogram per Hour). This 
endpoint was recorded for 32 study drug arms among 22 
studies including a wide range of surgeries.
Significant standardized mean differences (reduc-
tions in opioid use) were found for 16 of 28 active study 
drug arms (Hedges’ g = −0.84; 95% CI, −1.22 to −0.47, 
P < 0.001) (fig. 3). Subgroup analyses found a highest effect 
in scoliosis surgeries (Hedges’ g = −3.23; 95% CI, −5.01 
to −1.45, P < 0.001), intermediate effect sizes in thoracic 
and cardiac surgeries, (Hedges’ g = −0.90; 95% CI, −1.25 
to −0.55, P < 0.001), and very modest or insignificant 
effects in adenotonsillectomies (Hedges’ g = −0.47; 95% 
CI, −1.16 to 0.22, P = 0.18), and urological/abdominal 
procedures (Hedges’ g = −0.17; 95% CI −0.43 to 0.09, 
P = 0.20). Significant percent reductions in opioid use 
were found in 17 of 32 study drug arms. Intrathecal mor-
phine25 after spinal fusion showed the highest sparing 
effect and efficacy–burden relationship.
Percentage Requiring Rescue Medication. This endpoint 
was recorded for 21 study drug arms among 16 studies. It 
was used commonly for ambulatory/short-stay surgeries, 
including urologic surgeries and adenotonsillectomies, not 
at all for scoliosis surgery or thoracic surgery.
Percentage requiring rescue medication showed significant 
standardized mean difference from control in 11 of 21 treat-
ment arms (Hedges’ g = −0.83; 95% CI, −1.15 to −0.52; P < 
0.001). Subgroup analyses showed that the effect magnitude 
is higher for the adenotonsillectomies (Hedges’ g = −0.99; 
95% CI, −1.53 to −0.44; P < 0.001) (driven by one article)15 
and smaller for urological procedures (Hedges’ g = −0.42; 
95% CI, −0.89 to −0.05; P = 0.08). Ten of 21 study drug 
arms demonstrated significant percent opioid-sparing effect.
Time to First Rescue Medication (Minutes). This endpoint 
was recorded for 20 study drug arms among 15 studies. It was 
used commonly for ambulatory/short-stay surgeries, as well 
as in one open-heart surgery and one spinal fusion surgery.
Time to first rescue medication shows a strong mean dif-
ference in favor of the study drug versus control in 11 of 19 
treatment arms (Hedges’ g = −1.64; 95% CI, −2.43 to −0.84; 
P < 0.001). Subanalyses by the type of surgery found small 
differences in the magnitude of the effect for adenotonsil-
lectomies (Hedges’ g = −1.44; 95% CI, −2.80 to −0.09; 
P = 0.04), and urological procedures (Hedges’ g = −1.86; 
95% CI, −3.96 to −0.25; P = 0.08). Thirteen out of 20 
treatment arms demonstrated significant percentage opi-
oid-sparing effect. Overall, time to first rescue seems to be 
an outcome with high assay sensitivity in single-dose opi-
oid studies.
NSAID as the Study Drug 
Details of the 29 included articles (38 active study drug 
arms) can be seen in Section A2 of Supplemental Digital 
Content 1, http://links.lww.com/ALN/B91. The largest 
number of studies involved adenotonsillectomies (13 arti-
cles). Overall the degree of opioid-sparing effect of NSAIDs 
varied considerably.
Total Opioid Usage (Milligram per Kilogram per Hour). This 
endpoint was recorded for 21 study drug arms among 20 
studies. It was used commonly for adenotonsillectomies but 
also for one study involving idiopathic scoliosis surgery and 
one involving other types of orthopedic surgery. Significant 
standardized mean differences (reductions in opioid use) 
were found for 10 of 15 active study drug arms (Hedges’ g 
= −0.92; 95% CI, −1.32 to −0.52; P < 0.001) (fig. 4). The 
effect magnitude was found to be slightly higher in tonsil-
lectomy surgeries than the general mean (Hedges’ g = −1.15; 
95% CI, −1.92 to −0.38; P = 0.003). No other type of sur-
gery could be evaluated separately due to the small number 
of studies. Significant percent reductions in opioid use were 
found in 11 of 21 study drug arms.
Percentage Needing Rescue Medication. This endpoint was 
recorded for 26 study drug arms among 18 studies. It was 
used commonly for adenotonsillectomies. Percentage requir-
ing rescue medication showed significant standardized mean 
difference from control for 8 of 18 treatment arms (Hedges’ g 
= −0.52; 95% CI, −0.66 to −0.38; P < 0.001). Ten out of 17 
articles demonstrated significant percent opioid sparing effect.
Time to First Rescue Medication (Minutes). This endpoint 
was recorded for 15 study drug arms among 11 studies. It was 
used commonly for ambulatory/short-stay surgeries, mainly 
for adenotonsillectomies. Time to first rescue medication 
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Table 1. Selected Characteristics of Included Studies
Source Surgery
Intervention Drug Intervention Group Control Group Outcome Variables
Pain ScaleName Dose Route N
Mean 
Age (yr)
SD or  
Range
Type of  
Control N
Mean 
Age (yr)
SD or  
Range
Rescue  
Opioid
Total 
Dose % Min
Primary  
Outcome
Opioids
Ali (2008)15 Tonsillectomy Tramadol 1 mg/kg IV 30 7.53 1.88 Placebo control 30 7.61 1.93 Meperidine X “Rescue” medication—
number of requests
FACES
Dextromethorphan 1 mg/kg Oral 30 7.46 1.85
Antila (2006)16 Tonsillectomy Tramadol 1 mg/kg IV 15 11.9 2.40 Placebo control 15 12.5 1.90 Fentanyl X “Rescue” medication—
number of rescue
VAS
Ayatollahi (2012)17 Tonsillectomy Tramadol 2 mg/kg Infil 42 7.06 2.21 Placebo control 42 7.40 1.38 Fentanyl X Not clearly stated mCHEOPS
Batra (2008)18 Urological Fentanyl 0.25 μg/kg IT 14 0.62 0.24 Add on 14 0.56 0.29 Fentanyl X X “Rescue” medication—
Time to first rescue
VAS
Fentanyl 0.5 μg/kg IT 13 0.57 0.08
Fentanyl 1 μg/kg IT 15 0.63 0.29
Bean-Lijewski 
(1996)19
Other surgeries Meperidine 1 mg/kg IM 25 4.10 2.60 Placebo control 28 4.20 3.00 Meperidine X X X Not clearly stated CHEOPS
Campbell (1992)20 Urological Fentanyl 1 μg/kg Epidur 17 5.30 3.30 Add on 17 4.60 3.80 Morphine X X X “Rescue” medication—% 
that need rescue
N/A
Dawson (2001)21 Tonsillectomy Dextromethorphan 1 mg/kg Oral 19 7.02 1.98 Placebo control 21 7.75 2.70 Morphine X Not clearly stated N/A
Doyle (1993a)22 Appendectomy Morphine 20 μg kg−1 h−1 IV 20 10.2 (6–12) Placebo control 20 9.60 (6–12) Morphine X Not clearly stated 4 points  
self-report
Doyle (1993b)23 Appendectomy Morphine 4 μg kg−1 h−1 IV 15 10.4 (6.5–12.9) Placebo control 15 10.5 (8.70–12.1) Morphine X Not clearly stated mCHEOPS
Morphine 10 μg kg−1 h−1 IV 15 10.3 (7.2–12.4)
Eschertzhuber 
(2008)24
Scoliosis Morphine 5 μg/kg IT 14 15.0 2.00 Control 14 15.0 1.00 Piritamide X Not clearly stated VAS
Morphine 15 μg/kg IT 14 15.0 2.00
Gall (2001)25 Spinal fusion Morphine 2 μg/kg IT 10 17.0 3.00 Placebo control 10 15.0 4.00 Morphine X X “Rescue” medication—
total dose
VAS
Morphine 5 μg/kg IT 10 15.0 2.00
Ganesh (2008)26 Noncardiac  
thoracic
Fentanyl 2 μg/ml Epidur 16 0.18 0.07 Add on 16 0.18 0.14 Nalbuphine X X “Rescue” medication—
total dose
FACES
Hammer (2005)27 Open Heart Morphine 7 μg/kg Epidur 20 2.37 1.46 Control 20 2.36 1.56 Fentanyl X Pain score FACES
Hasan (2004)28 Tympanomastoid Dextromethorphan 1 mg/kg Oral 19 12.2 3.40 Placebo control 19 11.5 3.70 Morphine X “Rescue” medication—
total dose
VAS
Heiba (2012)29 Tonsillectomy Tramadol 2 mg/kg Infil 20 15.3 2.20 Placebo control 20 15.2 3.20 Meperidine X X Not clearly stated VAS
Kawaraguchi 
(2006)30
Urological Fentanyl 1 μg/kg Epidur 17 4.00 (3–6.92) Add on 18 4.30 (3.00–7.08) Pentazocine X X “Rescue” medication—
Time to first rescue
CHEOPS
Kim (2013)31 Urological Remifentanil 0.3 μg kg−1 min−1 IV 15 2.48 1.18 Placebo control 15 2.74 1.19 Remifentanil X “Rescue” medication—
total dose
mCHEOPS
Remifentanil 0.6 μg kg−1 min−1 IV 15 2.69 1.02
Remifentanil 0.9 μg kg−1 min−1 IV 15 2.72 1.31
Krane (1987)32 Other surgeries Morphine 0.1 mg/kg Epidur 15 7.70 NR Control 15 7.80 NR Morphine X X “Rescue” medication—
Time to first rescue
N/A
Lawhorn (1994)33 Other surgeries Butorphanol 40 μg/kg Epidur 10 8.50 5.30 Add on 10 8.60 4.70 Morphine X Not clearly stated N/A
Lawhorn (1997)34 Urological Butorphanol 30 μg/kg Epidur 100 4.09 2.57 Add on 100 3.97 2.37 Morphine X X Not clearly stated N/A
Mane (2011)35 Cleft palate repair Fentanyl 0.25 μg/kg Block 15 16.4 NR Add on 15 14.0 NR Fentanyl X Not clearly stated N/A
Meperidine 0.25 μg/kg Block 15 14.9 NR
McDonnell (2008)36 Ideopathic  
Scoliosis
Morphine 100 μg/kg IV 18 14.8 1.70 Placebo control 19 14.5 1.90 Morphine X “Rescue” medication—
total dose
N/A
Ozcengiz (2001)37 Urological Tramadol 2 mg/kg Epidur 38 6.85 1.80 Control 38 6.76 1.76 Morphine X Not clearly stated N/A
Morphine 0.03 mg/kg Epidur 40 6.97 1.76
Rosen (1989)38 Open Heart Morphine 0.075 mg/kg Epidur 16 2 to 12 NR Placebo control 16 2 to 12 NR Morphine X X Not clearly stated VAS
Rose (1999)39 Tonsillectomy Dextromethorphan 0.5 mg/kg Oral 19 7.80 1.70 Placebo control 19 7.90 1.60 Morphine X X “Rescue” medication—
total dose
VAS
Dextromethorphan 1 mg/kg Oral 19 7.90 1.60
Sharma (2011)40 Other surgeries Methadone 0.1 mg/kg IV 10 14.0 2.00 Control 30 15.0 2.00 Morphine X Pharmacokinetics Nurses pain 
scaleMethadone 0.2 mg/kg IV 10 13.0 2.00
Methadone 0.3 mg/kg IV 11 14.0 2.00
(Continued)
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Table 1. Selected Characteristics of Included Studies
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Intervention Drug Intervention Group Control Group Outcome Variables
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Type of  
Control N
Mean 
Age (yr)
SD or  
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Rescue  
Opioid
Total 
Dose % Min
Primary  
Outcome
Opioids
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Rose (1999)39 Tonsillectomy Dextromethorphan 0.5 mg/kg Oral 19 7.80 1.70 Placebo control 19 7.90 1.60 Morphine X X “Rescue” medication—
total dose
VAS
Dextromethorphan 1 mg/kg Oral 19 7.90 1.60
Sharma (2011)40 Other surgeries Methadone 0.1 mg/kg IV 10 14.0 2.00 Control 30 15.0 2.00 Morphine X Pharmacokinetics Nurses pain 
scaleMethadone 0.2 mg/kg IV 10 13.0 2.00
Methadone 0.3 mg/kg IV 11 14.0 2.00
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Suominen (2004)41 Open Heart Morphine 20 μg/kg IT 35 1.19 (0.01–16.7) Control 36 1.19 (0.03–12.7) Morphine X X X “Rescue” medication—% 
that need rescue
N/A
Suski (2010)42 Ideopathic  
Scoliosis
Dextromethorphan 30–45 mg Oral 30 15.9 2.40 Placebo control 30 16.5 2.70 Morphine X Not clearly stated NRS
Tarkkila (2003)43 Tonsillectomy Remifentanil 1 μg/kg IV 25 3.83 2.08 Placebo control 25 2.92 1.83 Oxycodone X X X Discharge time N/A
Ugur (2008)44 Tonsillectomy Tramadol 2 mg/kg IM 15 8.20 1.70 Placebo control 15 8.50 2.10 Meperidine X Pain score VAS
Tramadol 2 mg/kg Infil 15 8.40 1.60
Umuroglu (2004)45 Tonsillectomy Morphine 0.1 mg/kg IV 15 7.13 2.51 Placebo control 15 6.96 2.08 Meperidine X X Not clearly stated CHEOPS
Tramadol 1.5 mg/kg IV 15 6.06 2.08
Viitanen (2001)46 Tonsillectomy Tramadol 2 mg/kg IV 40 1 to 3 NR Placebo control 40 1 to 3 NR Meperidine X X X “Rescue” medication—% 
that need rescue
N/A
Watcha (1992)47 Other surgeries Morphine 0.1 mg/kg IV 31 8.50 3.70 Placebo control 32 10.0 3.60 Morphine X Not clearly stated VAS
Nonsteroidal 
antiinflam-
matory 
drugs
Adarsh (2012)48 Cleft palate repair Diclofenac 1 mg/kg Rectal 30 2.80 1.73 Control 30 2.26 1.43 Fentanyl X X “Rescue” medication—
total dose
Hannallah
Antila (2006)16 Tonsillectomy Ketoprofen 2 mg/kg IV 15 12.5 2.30 Placebo control 15 12.50 1.90 Fentanyl X “Rescue” medication—
number of doses
VAS
Bean-Lijewski 
(1996)19
Other surgeries Ketorolac 0.75 mg/kg IM 29 4.00 2.20 Placebo control 28 4.20 3.00 Meperidine X X X Not clearly stated CHEOPS
Bridge (2000)49 Strabismus Ketorolac 3 mg per eye Ophthalm 17 5.25 (4.25–9.75) Placebo control 13 6.67 (4.17–12.4) Morphine X X Pain score CHEOPS
Dawson (1996)50 Cleft palate repair Ketorolac 1 mg/kg + 0.5 mg/
kg QID
IV 18 7 to 20 NR Control 16 7 to 20 NR Morphine X Not clearly stated N/A
Kokki (1994)51 Elective surgery Ibuprofen 40 mg kg−1 day−1 Rectal 40 2.42 1.11 Placebo control 41 2.78 1.32 Morphine X X “Rescue” medication—
total dose
Maunuksela
Kokki (1998)52 Tonsillectomy Ketoprofen 0.3 mg/kg IV 55 3.33 (1.5–6.17) Placebo control 55 3.42 (1.25–6.58) Fentanyl X X “Rescue” medication—% 
that need rescue
Maunuksela
Ketoprofen 1 mg/kg IV 55 2.67 (1.25–7.08)
Ketoprofen 3 mg/kg IV 55 2.67 (1.25–6.00)
Kokki (1999a)53 Strabismus Ketoprofen 1 + 1 mg/kg IV 30 6.92 (4.17–9.33) Placebo control 29 5.33 (3.83–7.83) Fentanyl X X X Vomiting Maunuksela
Kokki (1999b)54 Major surgery Ketoprofen 1 + 4 mg/kg IV 24 6.58 (1.58–14.8) Placebo control 23 7.08 (1.25–14.4) Sulfentanyl X “Rescue” medication—
total dose
Maunuksela
Kokki (2000)55 Tonsillectomy Ketoprofen 25 mg/kg IV 42 3.67 (1.17–8.08) Placebo control 39 3.75 (1.17–6.08) Fentanyl X X “Rescue” medication—
total dose
Maunuksela
Ketoprofen 25 mg/kg Rectal 42 2.75 (1.42–2.25)
Kokki (2001)56 Tonsillectomy 
(phase I)
Ketoprofen 1 + 1 mg/kg IV 54 3.25 1.92 Placebo control 45 3.33 1.92 Fentanyl X Lenght of hospital stay VAS
Tonsillectomy 
(phase III)
Ketoprofen 0.3 mg/kg IV 33 3.50 1.75 Placebo control 35 4.00 2.25 Fentanyl X
Ketoprofen 1 mg/kg IV 29 3.25 2.17
Ketoprofen 3 mg/kg IV 32 3.08 1.83
Kokki (2002)57 Tonsillectomy Ketoprofen 0.5 + 3 mg/kg preqx IV 47 10.0 1.00 placebo control 20 11.0 1.00 Oxycodone X “Rescue” medication—% 
that need rescue
VAS
Ketoprofen 0.5 + 3 mg/kg 
postqx
IV 42 12.0 3.00
Kokki (2004)58 Strabismus Ketoprofen 1 + 1 mg/kg IV 27 7.92 2.92 Placebo control 29 7.17 3.00 Fentanyl X X “Rescue” medication—
number of doses
N/A
Korpela (2007)59 Tonsillectomy Naproxen 10 mg/kg Oral 30 1.80 (0.70–6.20) Placebo control 29 1.60 (0.80–5.90) Fentanyl X X X “Rescue” medication—% 
that need rescue
OPS
Morton (1999)60 Appendectomy Diclofenac 1 mg/kg TID Rectal 20 10.6 (6.00–13.0) Control 20 10.15 (5–13) Morphine X “Rescue” medication—
total dose
N/A
Munro (2002)61 Ideopathic  
scoliosis
Ketorolac 0.5 mg/kg IV 20 14.1 1.20 Placebo control 15 13.9 1.30 Morphine X Pain score VAS
Nikanne (1997)62 Tonsillectomy Ketoprofen 1 + 1 mg/kg IV 80 3.17 (1.00–9.25) Placebo control 84 3.33 (0.83–7.92) Fentanyl X X “Rescue” medication—% 
that need rescue
Maunuksela
Oztekin (2002)63 Tonsillectomy Diclofenac 1 mg/kg Rectal 20 8.40 0.53 Control 20 8.90 0.45 Morphine X Not clearly stated VAS
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Suominen (2004)41 Open Heart Morphine 20 μg/kg IT 35 1.19 (0.01–16.7) Control 36 1.19 (0.03–12.7) Morphine X X X “Rescue” medication—% 
that need rescue
N/A
Suski (2010)42 Ideopathic  
Scoliosis
Dextromethorphan 30–45 mg Oral 30 15.9 2.40 Placebo control 30 16.5 2.70 Morphine X Not clearly stated NRS
Tarkkila (2003)43 Tonsillectomy Remifentanil 1 μg/kg IV 25 3.83 2.08 Placebo control 25 2.92 1.83 Oxycodone X X X Discharge time N/A
Ugur (2008)44 Tonsillectomy Tramadol 2 mg/kg IM 15 8.20 1.70 Placebo control 15 8.50 2.10 Meperidine X Pain score VAS
Tramadol 2 mg/kg Infil 15 8.40 1.60
Umuroglu (2004)45 Tonsillectomy Morphine 0.1 mg/kg IV 15 7.13 2.51 Placebo control 15 6.96 2.08 Meperidine X X Not clearly stated CHEOPS
Tramadol 1.5 mg/kg IV 15 6.06 2.08
Viitanen (2001)46 Tonsillectomy Tramadol 2 mg/kg IV 40 1 to 3 NR Placebo control 40 1 to 3 NR Meperidine X X X “Rescue” medication—% 
that need rescue
N/A
Watcha (1992)47 Other surgeries Morphine 0.1 mg/kg IV 31 8.50 3.70 Placebo control 32 10.0 3.60 Morphine X Not clearly stated VAS
Nonsteroidal 
antiinflam-
matory 
drugs
Adarsh (2012)48 Cleft palate repair Diclofenac 1 mg/kg Rectal 30 2.80 1.73 Control 30 2.26 1.43 Fentanyl X X “Rescue” medication—
total dose
Hannallah
Antila (2006)16 Tonsillectomy Ketoprofen 2 mg/kg IV 15 12.5 2.30 Placebo control 15 12.50 1.90 Fentanyl X “Rescue” medication—
number of doses
VAS
Bean-Lijewski 
(1996)19
Other surgeries Ketorolac 0.75 mg/kg IM 29 4.00 2.20 Placebo control 28 4.20 3.00 Meperidine X X X Not clearly stated CHEOPS
Bridge (2000)49 Strabismus Ketorolac 3 mg per eye Ophthalm 17 5.25 (4.25–9.75) Placebo control 13 6.67 (4.17–12.4) Morphine X X Pain score CHEOPS
Dawson (1996)50 Cleft palate repair Ketorolac 1 mg/kg + 0.5 mg/
kg QID
IV 18 7 to 20 NR Control 16 7 to 20 NR Morphine X Not clearly stated N/A
Kokki (1994)51 Elective surgery Ibuprofen 40 mg kg−1 day−1 Rectal 40 2.42 1.11 Placebo control 41 2.78 1.32 Morphine X X “Rescue” medication—
total dose
Maunuksela
Kokki (1998)52 Tonsillectomy Ketoprofen 0.3 mg/kg IV 55 3.33 (1.5–6.17) Placebo control 55 3.42 (1.25–6.58) Fentanyl X X “Rescue” medication—% 
that need rescue
Maunuksela
Ketoprofen 1 mg/kg IV 55 2.67 (1.25–7.08)
Ketoprofen 3 mg/kg IV 55 2.67 (1.25–6.00)
Kokki (1999a)53 Strabismus Ketoprofen 1 + 1 mg/kg IV 30 6.92 (4.17–9.33) Placebo control 29 5.33 (3.83–7.83) Fentanyl X X X Vomiting Maunuksela
Kokki (1999b)54 Major surgery Ketoprofen 1 + 4 mg/kg IV 24 6.58 (1.58–14.8) Placebo control 23 7.08 (1.25–14.4) Sulfentanyl X “Rescue” medication—
total dose
Maunuksela
Kokki (2000)55 Tonsillectomy Ketoprofen 25 mg/kg IV 42 3.67 (1.17–8.08) Placebo control 39 3.75 (1.17–6.08) Fentanyl X X “Rescue” medication—
total dose
Maunuksela
Ketoprofen 25 mg/kg Rectal 42 2.75 (1.42–2.25)
Kokki (2001)56 Tonsillectomy 
(phase I)
Ketoprofen 1 + 1 mg/kg IV 54 3.25 1.92 Placebo control 45 3.33 1.92 Fentanyl X Lenght of hospital stay VAS
Tonsillectomy 
(phase III)
Ketoprofen 0.3 mg/kg IV 33 3.50 1.75 Placebo control 35 4.00 2.25 Fentanyl X
Ketoprofen 1 mg/kg IV 29 3.25 2.17
Ketoprofen 3 mg/kg IV 32 3.08 1.83
Kokki (2002)57 Tonsillectomy Ketoprofen 0.5 + 3 mg/kg preqx IV 47 10.0 1.00 placebo control 20 11.0 1.00 Oxycodone X “Rescue” medication—% 
that need rescue
VAS
Ketoprofen 0.5 + 3 mg/kg 
postqx
IV 42 12.0 3.00
Kokki (2004)58 Strabismus Ketoprofen 1 + 1 mg/kg IV 27 7.92 2.92 Placebo control 29 7.17 3.00 Fentanyl X X “Rescue” medication—
number of doses
N/A
Korpela (2007)59 Tonsillectomy Naproxen 10 mg/kg Oral 30 1.80 (0.70–6.20) Placebo control 29 1.60 (0.80–5.90) Fentanyl X X X “Rescue” medication—% 
that need rescue
OPS
Morton (1999)60 Appendectomy Diclofenac 1 mg/kg TID Rectal 20 10.6 (6.00–13.0) Control 20 10.15 (5–13) Morphine X “Rescue” medication—
total dose
N/A
Munro (2002)61 Ideopathic  
scoliosis
Ketorolac 0.5 mg/kg IV 20 14.1 1.20 Placebo control 15 13.9 1.30 Morphine X Pain score VAS
Nikanne (1997)62 Tonsillectomy Ketoprofen 1 + 1 mg/kg IV 80 3.17 (1.00–9.25) Placebo control 84 3.33 (0.83–7.92) Fentanyl X X “Rescue” medication—% 
that need rescue
Maunuksela
Oztekin (2002)63 Tonsillectomy Diclofenac 1 mg/kg Rectal 20 8.40 0.53 Control 20 8.90 0.45 Morphine X Not clearly stated VAS
Table 1. (Continued)
Source Surgery
Intervention Drug Intervention Group Control Group Outcome Variables
Pain ScaleName Dose Route N
Mean 
Age (yr)
SD or  
Range
Type of  
Control N
Mean 
Age (yr)
SD or  
Range
Rescue  
Opioid
Total 
Dose % Min
Primary  
Outcome
(Continued ) 
Anesthesiology 2015; 122:150-71 158 Kossowsky et al.
Rescue Designs for Pediatric Analgesic Trials
Ryhanen (1994)64 Urological Diclofenac 1 mg/kg IM 70 3.80 1.70 Control 73 3.50 1.80 Meperidine X X Not clearly stated N/A
Rugyte (2007)65 Pectus Ketoprofen 1 mg/kg IV 14 14.00 (13.0–15.0) Placebo control 17 13.0 (10–15) Morphine X “Rescue” medication—
total dose
VAS
Sheeran (2004)66 Tonsillectomy Rofecoxib 0.5 mg/kg Oral 23 7.20 1.80 Placebo control 22 7.60 2.20 Morphine X “Rescue” medication—
total dose
CHEOPS
Sims (1994)67 Abdominal Indomethacin 2 mg/kg Rectal 13 10.1 1.80 Placebo control 15 10.7 2.10 Morphine X Not clearly stated VAS
Sutters (1995)68 Tonsillectomy Ketorolac 1 mg/kg IM 45 7.06 2.41 Placebo control 42 7.08 2.22 Fentanyl X X “Rescue” medication CHEOPS
Sutters(1999)69 Orthopedic  
Surgery
Ketorolac 1 mg/kg + 0.5 mg/
kg QID
IV 36 12.7 3.51 Placebo control 32 12.67 4.22 Morphine X Not clearly stated FACES
Tuomilehto (2000)70 Adenoidectomy Ketoprofen 1 mg/kg IV 40 2.67 (1.33–6.83) Placebo control 20 3.83 (1.25–8.42) Fentanyl X X “Rescue” medication—% 
that need rescue
Maunuksela
Ketoprofen 1 mg/kg Oral 40 4.17 (1.67–8.42)
Tuomilehto (2002)71 Tonsillectomy Ketoprofen 2 mg/kg IM 40 3.50 (1.00–8.33) Placebo control 40 2.75 (1.33–7.08) Fentanyl X X “Rescue” medication—% 
that need rescue
OPS
Ketoprofen 2 mg/kg IV 40 2.50 (1.25–6.25)
Vetter (1994)72 Orthopedics Ketorolac 0.8 mg/kg IV 25 13.0 2.00 Control 25 13.0 2.30 Morphine X X Not clearly stated VAS
Viitanen (2003)73 Tonsillectomy Ibuprofen 15 mg/kg Rectal 41 3.20 (1.00–6.90) Placebo control 38 2.60 (1.00–6.00) Meperidine X X “Rescue” medication—% 
that need rescue
N/A
Watcha (1992)47 Other surgeries Ketorolac 0.9 mg/kg IV 32 8.3 3.80 Placebo control 32 10.0 3.60 Morphine X Not clearly stated VAS
Acetami-
nophen
Bremerich (2001)74 Cleft palate Acetaminophen 10 mg/kg Rectal 20 0.97 0.73 Placebo control 20 1.04 0.97 Piritramide X Not clearly stated CHIPPS
Acetaminophen 20 mg/kg Rectal 20 1.01 0.87
Acetaminophen 40 mg/kg Rectal 20 0.79 0.75
Dashti (2009)75 Tonsillectomy Acetaminophen 40 mg/kg Rectal 53 10.2 2.84 Control 51 9.45 2.22 Meperidine X X Not clearly stated VAS
Gandhi (2012)76 Ophthalmic Acetaminophen 40 mg/kg Rectal 48 5.60 3.40 Control 30 6.60 4.15 Fentanyl X X Pain score OPS
Acetaminophen 20 mg/kg 47 7.40 3.40
Hiller (2012)77 Spine Acetaminophen 30 mg/kg IV 18 15.1 2.00 Placebo control 18 14.4 1.90 Oxycodone X X X “Rescue” medication—
total dose
N/A
Kocum (2013)78 Tonsillectomy Acetaminophen 15 mg/kg IV 40 4.70 1.00 Placebo control 40 4.30 1.00 Meperidine X “Rescue” medication—
total dose
CHEOPS
Korpela (1999)79 Elective surgery Acetaminophen 20 mg/kg Rectal 30 3.10 1.90 Placebo control 30 4.40 2.10 Morphine X X Not clearly stated VAS
Acetaminophen 40 mg/kg Rectal 30 3.80 2.20
Acetaminophen 60 mg/kg Rectal 30 4.20 2.30
Korpela (2007)59 Tonsillectomy Acetaminophen 10 mg/kg Oral 30 1.30 (0.80–5.60) Placebo control 29 1.60 (0.80–5.90) Fentanyl X X X “Rescue” medication—% 
that need rescue
OPS
Mercan (2007)80 Inguinal Acetaminophen 20–25 mg/kg p3 Rectal 65 4.00 2.97 Control 59 3.97 2.92 Meperidine X Not clearly stated VAS
Acetaminophen 20–25 mg/kg p4 Rectal 78 3.92 2.93
Morton (1999)60 Appendectomy Acetaminophen 20 mg/kg + 15 mg/
kg QID
Rectal 20 9.90 (5.00–12.0) Control 20 10.15 (5.00–13.0) Morphine X “Rescue” medication—
total dose
N/A
Van der Marel 
(2007)81
Abdominal Acetaminophen 30–40 mg/kg + 
20 mg/kg QID
Rectal 29 0.00 (0.00–0.25) Placebo control 25 0.00 (0.00–0.08) Morphine X “Rescue” medication VAS
Viitanen (2003)73 Tonsillectomy Acetaminophen 40 mg/kg Rectal 40 2.70 (1.00–6.40) Placebo control 38 2.60 (1.00–6.00) Meperidine X X “Rescue” medication—% 
that need rescue
N/A
Local anes-
thetics
Carney (2010)82 Appendectomy Ropivacaine 0.75% 2.5 mg/kg Block 19 NR (4.00–16.0) Placebo control 21 NR (5–16) Morphine X X “Rescue” medication—
total dose
CHIPPS
Chaudhary (2012)83 Cardiac Ropicacine 0.5% 0.05–0.06 mg/kg Block 14 5.50 1.82 Placebo control 13 5.70 1.58 Fentanyl X Pain score mOPS
Coban (2008)84 Cleft palate Ropivacaine 0.2 mg/kg Infil 10 1.90 1.00 Control 10 1.80 0.80 Morphine X X Not clearly stated CHIPPS
Edwards (2011)85 Appendectomy Bupivacaine 0.25% 0.5 ml/kg Infil 29 11.8 (10.8–12.9) Placebo control 29 12.3 (11.3–13.3) Morphine X X Pain score FACES
Control 30 11.9 (10.8–13.1)
Giannoni (2001)86 Tonsillectomy Ropivacaine 0.01% 0.15 ml/kg Infil 21 7.00 2.90 Placebo control 21 7.40 3.70 Fentanyl X Pain score VAS
Heiba (2012)29 Tonsillectomy Lidocaine 2 mg/kg Infil 20 14.9 2.50 Placebo control 20 15.2 3.20 Meperidine X X Not clearly stated VAS
Hermansson 
(2013)87
Abdominal Bupivacaine 0.2–0.4 mg kg−1 h−1 SC infu-
sion
17 3.40 (0.50–12.6) Placebo control 15 2.80 (0.6–5.8) Morphine X “Rescue” medication—
number of doses
N/A
Inanoglu (2009)88 Tonsillectomy Bupivacaine 0.25% NR Infil 30 6.00 1.30 Placebo control 30 6.20 1.60 Fentanyl X X Pain score CHEOPS
Table 1. (Continued)
Source Surgery
Intervention Drug Intervention Group Control Group Outcome Variables
Pain ScaleName Dose Route N
Mean 
Age (yr)
SD or  
Range
Type of  
Control N
Mean 
Age (yr)
SD or  
Range
Rescue  
Opioid
Total 
Dose % Min
Primary  
Outcome
(Continued)
Anesthesiology 2015; 122:150-71 159 Kossowsky et al.
PAIN MeDICINe
Ryhanen (1994)64 Urological Diclofenac 1 mg/kg IM 70 3.80 1.70 Control 73 3.50 1.80 Meperidine X X Not clearly stated N/A
Rugyte (2007)65 Pectus Ketoprofen 1 mg/kg IV 14 14.00 (13.0–15.0) Placebo control 17 13.0 (10–15) Morphine X “Rescue” medication—
total dose
VAS
Sheeran (2004)66 Tonsillectomy Rofecoxib 0.5 mg/kg Oral 23 7.20 1.80 Placebo control 22 7.60 2.20 Morphine X “Rescue” medication—
total dose
CHEOPS
Sims (1994)67 Abdominal Indomethacin 2 mg/kg Rectal 13 10.1 1.80 Placebo control 15 10.7 2.10 Morphine X Not clearly stated VAS
Sutters (1995)68 Tonsillectomy Ketorolac 1 mg/kg IM 45 7.06 2.41 Placebo control 42 7.08 2.22 Fentanyl X X “Rescue” medication CHEOPS
Sutters(1999)69 Orthopedic  
Surgery
Ketorolac 1 mg/kg + 0.5 mg/
kg QID
IV 36 12.7 3.51 Placebo control 32 12.67 4.22 Morphine X Not clearly stated FACES
Tuomilehto (2000)70 Adenoidectomy Ketoprofen 1 mg/kg IV 40 2.67 (1.33–6.83) Placebo control 20 3.83 (1.25–8.42) Fentanyl X X “Rescue” medication—% 
that need rescue
Maunuksela
Ketoprofen 1 mg/kg Oral 40 4.17 (1.67–8.42)
Tuomilehto (2002)71 Tonsillectomy Ketoprofen 2 mg/kg IM 40 3.50 (1.00–8.33) Placebo control 40 2.75 (1.33–7.08) Fentanyl X X “Rescue” medication—% 
that need rescue
OPS
Ketoprofen 2 mg/kg IV 40 2.50 (1.25–6.25)
Vetter (1994)72 Orthopedics Ketorolac 0.8 mg/kg IV 25 13.0 2.00 Control 25 13.0 2.30 Morphine X X Not clearly stated VAS
Viitanen (2003)73 Tonsillectomy Ibuprofen 15 mg/kg Rectal 41 3.20 (1.00–6.90) Placebo control 38 2.60 (1.00–6.00) Meperidine X X “Rescue” medication—% 
that need rescue
N/A
Watcha (1992)47 Other surgeries Ketorolac 0.9 mg/kg IV 32 8.3 3.80 Placebo control 32 10.0 3.60 Morphine X Not clearly stated VAS
Acetami-
nophen
Bremerich (2001)74 Cleft palate Acetaminophen 10 mg/kg Rectal 20 0.97 0.73 Placebo control 20 1.04 0.97 Piritramide X Not clearly stated CHIPPS
Acetaminophen 20 mg/kg Rectal 20 1.01 0.87
Acetaminophen 40 mg/kg Rectal 20 0.79 0.75
Dashti (2009)75 Tonsillectomy Acetaminophen 40 mg/kg Rectal 53 10.2 2.84 Control 51 9.45 2.22 Meperidine X X Not clearly stated VAS
Gandhi (2012)76 Ophthalmic Acetaminophen 40 mg/kg Rectal 48 5.60 3.40 Control 30 6.60 4.15 Fentanyl X X Pain score OPS
Acetaminophen 20 mg/kg 47 7.40 3.40
Hiller (2012)77 Spine Acetaminophen 30 mg/kg IV 18 15.1 2.00 Placebo control 18 14.4 1.90 Oxycodone X X X “Rescue” medication—
total dose
N/A
Kocum (2013)78 Tonsillectomy Acetaminophen 15 mg/kg IV 40 4.70 1.00 Placebo control 40 4.30 1.00 Meperidine X “Rescue” medication—
total dose
CHEOPS
Korpela (1999)79 Elective surgery Acetaminophen 20 mg/kg Rectal 30 3.10 1.90 Placebo control 30 4.40 2.10 Morphine X X Not clearly stated VAS
Acetaminophen 40 mg/kg Rectal 30 3.80 2.20
Acetaminophen 60 mg/kg Rectal 30 4.20 2.30
Korpela (2007)59 Tonsillectomy Acetaminophen 10 mg/kg Oral 30 1.30 (0.80–5.60) Placebo control 29 1.60 (0.80–5.90) Fentanyl X X X “Rescue” medication—% 
that need rescue
OPS
Mercan (2007)80 Inguinal Acetaminophen 20–25 mg/kg p3 Rectal 65 4.00 2.97 Control 59 3.97 2.92 Meperidine X Not clearly stated VAS
Acetaminophen 20–25 mg/kg p4 Rectal 78 3.92 2.93
Morton (1999)60 Appendectomy Acetaminophen 20 mg/kg + 15 mg/
kg QID
Rectal 20 9.90 (5.00–12.0) Control 20 10.15 (5.00–13.0) Morphine X “Rescue” medication—
total dose
N/A
Van der Marel 
(2007)81
Abdominal Acetaminophen 30–40 mg/kg + 
20 mg/kg QID
Rectal 29 0.00 (0.00–0.25) Placebo control 25 0.00 (0.00–0.08) Morphine X “Rescue” medication VAS
Viitanen (2003)73 Tonsillectomy Acetaminophen 40 mg/kg Rectal 40 2.70 (1.00–6.40) Placebo control 38 2.60 (1.00–6.00) Meperidine X X “Rescue” medication—% 
that need rescue
N/A
Local anes-
thetics
Carney (2010)82 Appendectomy Ropivacaine 0.75% 2.5 mg/kg Block 19 NR (4.00–16.0) Placebo control 21 NR (5–16) Morphine X X “Rescue” medication—
total dose
CHIPPS
Chaudhary (2012)83 Cardiac Ropicacine 0.5% 0.05–0.06 mg/kg Block 14 5.50 1.82 Placebo control 13 5.70 1.58 Fentanyl X Pain score mOPS
Coban (2008)84 Cleft palate Ropivacaine 0.2 mg/kg Infil 10 1.90 1.00 Control 10 1.80 0.80 Morphine X X Not clearly stated CHIPPS
Edwards (2011)85 Appendectomy Bupivacaine 0.25% 0.5 ml/kg Infil 29 11.8 (10.8–12.9) Placebo control 29 12.3 (11.3–13.3) Morphine X X Pain score FACES
Control 30 11.9 (10.8–13.1)
Giannoni (2001)86 Tonsillectomy Ropivacaine 0.01% 0.15 ml/kg Infil 21 7.00 2.90 Placebo control 21 7.40 3.70 Fentanyl X Pain score VAS
Heiba (2012)29 Tonsillectomy Lidocaine 2 mg/kg Infil 20 14.9 2.50 Placebo control 20 15.2 3.20 Meperidine X X Not clearly stated VAS
Hermansson 
(2013)87
Abdominal Bupivacaine 0.2–0.4 mg kg−1 h−1 SC infu-
sion
17 3.40 (0.50–12.6) Placebo control 15 2.80 (0.6–5.8) Morphine X “Rescue” medication—
number of doses
N/A
Inanoglu (2009)88 Tonsillectomy Bupivacaine 0.25% NR Infil 30 6.00 1.30 Placebo control 30 6.20 1.60 Fentanyl X X Pain score CHEOPS
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shows a moderate mean difference in favor of the study drug 
versus control in one of four treatment arms (Hedges’ g = 
−0.32; 95% CI, −0.53 to −0.10; P = 0.004). Since there were 
only four studies that could be included, no subgroup analyses 
could be conducted. Only 2 of 11 treatment arms demon-
strated significant percent opioid-sparing effect and one article 
had a slightly negative, yet nonsignificant sparing effect.53
Overall, total opioid dose in milligram per kilogram per 
hour seems to be the opioid-sparing outcome with the high-
est assay sensitivity for NSAID trials.
Acetaminophen as the Study Drug 
Details of the 11 included articles (17 active study drug 
arms) can be seen in Section A2 of Supplemental Digital 
Content 1, http://links.lww.com/ALN/B91. General con-
clusions were (1) rectal acetaminophen showed greatest 
effect size in all three measures at doses of 40 or 60 mg/kg, 
and variable effects at lower doses; and (2) only one oral and 
two IV acetaminophen studies met full inclusion criteria for 
this review; effect size using IV acetaminophen was strongly 
influenced by study methodology.
Total Opioid Usage (Milligram per Kilogram per Hour). 
This endpoint was recorded for 13 study drug arms among 
9 studies. It was used commonly for ambulatory/short-stay 
surgeries. Significant standardized mean differences (reduc-
tions in opioid use) were found for four of eight active study 
drug arms (Hedges’ g = −2.12; 95% CI, −3.50 to −0.75; 
P = 0.002) (fig. 5), though this was heavily influenced by 
the effectiveness of 40 and 60 mg/kg in the study by Korpela 
et al.79 Significant percent reductions in opioid use were 
found in 4 of 13 study drug arms.
Percentage Needing Rescue Medication. This endpoint 
was recorded for 10 study drug arms among 6 studies. It 
was used commonly to evaluate rectal acetaminophen in 
ambulatory/short-stay surgeries. Percentage requiring res-
cue medication showed significant standardized mean dif-
ference from control in 5 of 10 treatment arms (Hedges’ 
g = −0.82; 95% CI, −1.20 to −0.44; P < 0.001). Note-
worthy, the effects sizes found in the study reported by 
Jagannathan 
(2009)89
Urological Bupivacaine 0.25% 0.1 ml/kg Block 25 3.62 1.87 Add on 23 4.14 1.89 Morphine X X Pain score CHIPPS
Klamt (2003)90 Abdominal Ropivacaine 0.1% 0.2 ml kg−1 h\−1 Epidur 17 2.82 2.67 Add on 18 3.53 2.83 Tramadol X X Not clearly stated N/A
Krane (1987)32 Other surgeries Bupivacaine 0.25% 0.1 ml/kg Epidur 13 6.20 NR Control 15 7.80 NR Morphine X X “Rescue” medication—
Time to first rescue
N/A
Kundra (2006)91 Inguinal hernia Bupivacaine 0.25% 0.25 ml/kg ILIH-I 34 6.10 3.60 Placebo control 34 5.20 3.30 Fentanyl X X “Rescue” medication—
total dose
APDS
Bupivacaine 0.25% 0.25 ml/kg ILIH-M 34 5.80 3.10
Bupivacaine 0.25% 0.25 ml/kg ILIH-S 34 5.80 3.70
Meara (2010)92 Cleft palate Bupivacaine 0.25% 1 ml/h SC  
infusion
32 6 to 9 NR Placebo control 33 6 to 9 NR Morphine X Pain score FACES
Muthukumar 
(2012)93
Cleft palate Lidocaine 7 mg/kg Infil 25 2.10 1.70 Placebo control 25 2.70 2.10 Fentanyl X Cardiovascular response FLACC
Lidocaine 7 mg/kg Infil 25 2.60 1.90 25 2.90 2.10
O´hara (2004)94 Spinal Bupivacaine 0.1% 4 ml/h Epidur 10 13 to 21 NR Placebo control 9 13 to 21 NR Morphine X Not clearly stated VAS
Bupivacaine 0.065% 4 ml/h Epidur 12 13 to 21 NR
Park (2004)95 Tonsillectomy Ropivacaine 0.5% 30 mg Infil 66 7.00 2.00 Placebo control 64 7.00 3.00 Fentanyl X Pain score OPS
Ryhanen (1994)64 Urological Bupivacaine 0.25% 1 ml/kg Epidur 57 3.90 1.80 Control 73 3.50 1.80 Meperidine X X Not clearly stated N/A
Bupivacaine 0.25% + 
Epinephrine
1 ml/kg Epidur 50 3.90 1.80
Splinter (2010)96 Appendectomy Ropivacaine 0.2% 0.25–0.5 ml/kg Block 18 10.2 3.00 Placebo control 18 10.6 2.90 Morphine X X “Rescue” medication—
total dose
N/A
Tirotta (2009)97 Cardiac Bupivacaine 0.25% /
Levobupivacaine
0.5–5 ml/h SC  
infusion
35 4.47 (0.25–14.7) Placebo control 37 3.51 (0.25–16.7) Morphine X X “Rescue” medication—
total dose
N/A
Usmani (2009)98 Urological EMLA cream 5% Topical 30 6.00 2.00 Placebo control 30 7.00 3.00 Fentanyl X X “Rescue” medication—
number of doses
N/A
Lidocaine 1% 0.5 ml/kg IV 30 7.00 2.00
APDS = All India Institute of Medical Sciences pain discomfort scale; CHEOPs = Children’s Hospital of Eastern Ontario Pain Scale; CHIPPS = Children and 
Infants Postoperative Pain Scale; Epidur = epidural; Faces = The Wong-Baker FACES® Pain Rating Scale; FLACC = The Face, Legs, Activity, Cry, Consolability 
scale; ILIH-I = inferomedial approach to ilioinguinal–iliohypogastric nerve block; ILIH-M = medial approach to ilioinguinal–iliohypogastric nerve block; ILIH-S = 
superomedial approach to ilioinguinal–iliohypogastric nerve block; IM = intramuscular; Infil = infiltration; IT = intrathecal; IV = intravenous; mCHEOPs = modi-
fied CHEOPs; mOPS = modified OPS; N/A = not applicable; NRS = numeric rate scale; Ophthalm = ophthalmological drops; OPS = Observational Pain Scale; 
SC infusion = subcutaneous infusion; VAS = visual analog scale.
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Korpela et al.79 were much smaller compared to the previ-
ous outcome and similar to the group mean. Four of six 
study drug arms demonstrated significant percent opioid-
sparing effect.
Time to First Rescue Medication (Minutes). This endpoint 
was recorded for five study drug arms among four studies. 
Time to first rescue medication shows no effect in favor of 
the study drug versus control in any arms (Hedges’ g = −0.07; 
95% CI, −0.32 to 0.19; P = 0.60). Since there were only 
four studies that could be included, no subgroup analyses 
could be conducted. No study found any percent differences 
between the study drug and control, including even those 
finding significant differences for 40 mg/kg rectal acetamin-
ophen when assessing total rescue opioid usage.59,73
Overall, for acetaminophen trials, total opioid dose in 
milligram per kilogram per hour seems to be the outcome 
with the highest assay sensitivity, yet due to low number of 
studies, these results should be considered preliminary.
Local Anesthetics as the Study Drug 
Details of the general characteristic of the 20 included arti-
cles (27 active study drug arms) can be seen in Section A2 
of Supplemental Digital Content 1, http://links.lww.com/
ALN/B91.
Total Opioid Usage (Milligram per Kilogram per Hour). This 
endpoint was recorded for 18 study drug arms among 13 
studies. Half of the articles administered the local anesthetics 
via infiltration and the other half via peripheral block or epi-
dural. Significant standardized mean differences (reductions 
in opioid use) were found for 6 of 14 active study drug arms 
(Hedges’ g = −0.72; 95% CI, −1.18 to −0.27; P = 0.002) 
(fig. 6). Abdominal surgeries (including inguinal hernia pro-
cedures) showed a nonsignificant effect (Hedges’ g = −0.40; 
95% CI, −1.01 to 0.20; P = 0.19). No other type of surgery 
could be evaluated due to the low number of studies. Single-
dose studies showed significant standardized mean differences 
(Hedges’ g = −1.16 95% CI, −1.85 to −0.47; P = 0.001), 
whereas studies evaluating continuous infusion showed 
none (Hedges’ g = −0.16; 95% CI, −0.55 to 0.22; P = 0.41). 
Jagannathan 
(2009)89
Urological Bupivacaine 0.25% 0.1 ml/kg Block 25 3.62 1.87 Add on 23 4.14 1.89 Morphine X X Pain score CHIPPS
Klamt (2003)90 Abdominal Ropivacaine 0.1% 0.2 ml kg−1 h\−1 Epidur 17 2.82 2.67 Add on 18 3.53 2.83 Tramadol X X Not clearly stated N/A
Krane (1987)32 Other surgeries Bupivacaine 0.25% 0.1 ml/kg Epidur 13 6.20 NR Control 15 7.80 NR Morphine X X “Rescue” medication—
Time to first rescue
N/A
Kundra (2006)91 Inguinal hernia Bupivacaine 0.25% 0.25 ml/kg ILIH-I 34 6.10 3.60 Placebo control 34 5.20 3.30 Fentanyl X X “Rescue” medication—
total dose
APDS
Bupivacaine 0.25% 0.25 ml/kg ILIH-M 34 5.80 3.10
Bupivacaine 0.25% 0.25 ml/kg ILIH-S 34 5.80 3.70
Meara (2010)92 Cleft palate Bupivacaine 0.25% 1 ml/h SC  
infusion
32 6 to 9 NR Placebo control 33 6 to 9 NR Morphine X Pain score FACES
Muthukumar 
(2012)93
Cleft palate Lidocaine 7 mg/kg Infil 25 2.10 1.70 Placebo control 25 2.70 2.10 Fentanyl X Cardiovascular response FLACC
Lidocaine 7 mg/kg Infil 25 2.60 1.90 25 2.90 2.10
O´hara (2004)94 Spinal Bupivacaine 0.1% 4 ml/h Epidur 10 13 to 21 NR Placebo control 9 13 to 21 NR Morphine X Not clearly stated VAS
Bupivacaine 0.065% 4 ml/h Epidur 12 13 to 21 NR
Park (2004)95 Tonsillectomy Ropivacaine 0.5% 30 mg Infil 66 7.00 2.00 Placebo control 64 7.00 3.00 Fentanyl X Pain score OPS
Ryhanen (1994)64 Urological Bupivacaine 0.25% 1 ml/kg Epidur 57 3.90 1.80 Control 73 3.50 1.80 Meperidine X X Not clearly stated N/A
Bupivacaine 0.25% + 
Epinephrine
1 ml/kg Epidur 50 3.90 1.80
Splinter (2010)96 Appendectomy Ropivacaine 0.2% 0.25–0.5 ml/kg Block 18 10.2 3.00 Placebo control 18 10.6 2.90 Morphine X X “Rescue” medication—
total dose
N/A
Tirotta (2009)97 Cardiac Bupivacaine 0.25% /
Levobupivacaine
0.5–5 ml/h SC  
infusion
35 4.47 (0.25–14.7) Placebo control 37 3.51 (0.25–16.7) Morphine X X “Rescue” medication—
total dose
N/A
Usmani (2009)98 Urological EMLA cream 5% Topical 30 6.00 2.00 Placebo control 30 7.00 3.00 Fentanyl X X “Rescue” medication—
number of doses
N/A
Lidocaine 1% 0.5 ml/kg IV 30 7.00 2.00
APDS = All India Institute of Medical Sciences pain discomfort scale; CHEOPs = Children’s Hospital of Eastern Ontario Pain Scale; CHIPPS = Children and 
Infants Postoperative Pain Scale; Epidur = epidural; Faces = The Wong-Baker FACES® Pain Rating Scale; FLACC = The Face, Legs, Activity, Cry, Consolability 
scale; ILIH-I = inferomedial approach to ilioinguinal–iliohypogastric nerve block; ILIH-M = medial approach to ilioinguinal–iliohypogastric nerve block; ILIH-S = 
superomedial approach to ilioinguinal–iliohypogastric nerve block; IM = intramuscular; Infil = infiltration; IT = intrathecal; IV = intravenous; mCHEOPs = modi-
fied CHEOPs; mOPS = modified OPS; N/A = not applicable; NRS = numeric rate scale; Ophthalm = ophthalmological drops; OPS = Observational Pain Scale; 
SC infusion = subcutaneous infusion; VAS = visual analog scale.
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Significant percent reductions in opioid use were found in 
10 of 18 study drug arms.
Percentage Needing Rescue Medication. This endpoint 
was recorded for 15 study drug arms among 10 studies. It 
was used most commonly for abdominal/urological surger-
ies. Percentage requiring rescue medication showed signifi-
cant standardized mean difference from control for 11 of 
15 treatment arms (Hedges’ g = −1.19; 95% CI, −1.56 to 
−0.82; P < 0.001). Abdominal surgeries (including ingui-
nal hernia procedures) were very close to the mean value 
(Hedges’ g = −1.21; 95% CI, −1.72 to −0.70; P < 0.001). 
No other type of surgery could be evaluated due to the small 
number of studies. Eight of 15 study drug arms demon-
strated significant percent opioid-sparing effect.
Time to First Rescue Medication (Minutes). This endpoint 
was recorded for 12 study drug arms among 10 studies. It 
was used most commonly for abdominal/urological sur-
geries. Time to first rescue medication shows a strong dif-
ference in favor of the study drug versus control in 9 of 10 
treatment arms (Hedges’ g = −1.55; 95% CI, −2.11 to −0.99; 
P < 0.001). In subgroup analyses, the urological and abdomi-
nal procedures show a smaller magnitude of the effect (Hedges’ 
Fig. 3. Forest plot for opioids as study drug. Expressed as Hedges’ g score and 95% CIs. Negative scores favor study drug over 
control. *Study included more than one active treatment arm.
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Fig. 4. Forest plot for nonsteroidal antiinflammatory drugs as study drug. Expressed as Hedges’ g score and 95% CIs. Negative 
scores favor study drug over control. *Study included more than one active treatment arm.
Fig. 5. Forest plot for acetaminophen as study drug. Expressed as Hedges’ g score and 95% CIs. Negative scores favor study 
drug over control. *Study included more than one active treatment arm.
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g = −1.05; 95% CI, −1.45 to −0.65; P < 0.001). Nine of 12 
treatment arms demonstrated significant percent opioid-spar-
ing effect.
Local anesthetic trials were highly variable. They 
involved wound infiltration (9 of 20 articles, two of those 
with continuous subcutaneous infusion), peripheral nerve 
blocks (5 of 20 articles), and epidural blocks (4 of 20 
articles, only one of those with continuous infusion). 
Some involved single injection, others involved continu-
ous infusions.
Pain Scores
Among the entire group of 85 clinical trials, 62 reported pain 
scores. Mean pain scores were 2.3 ± 1.5 in the study drug arms 
and 3.4 ± 1.2 in the control arms (P < 0.001). Eighteen trials 
used PCA or NCA, whereas 44 administered rescue analge-
sia by nurse-administered boluses. No statistical differences 
were found between PCA/NCA and nurse-administered res-
cue trials on pain scores in the study drug arms (2.5 ± 1.3 
vs. 2.2 ± 1.6; P = 0.43) and in the control arms (3.4 ± 1.5 vs. 
3.3 ± 2.1; P = 0.84). Studies using observational measures did 
not differ from those using self-report measures (3.6 ± 1.7 vs. 
3.1 ± 2.1; P = 0.25). No trial using PCA/NCA had a mean 
pain score greater than five in either study arm or control 
arm. Similar results for the pain score measures were found 
when using parametric and nonparametric methods.
A linear regression found no associations between pain 
scores in the control group and type of surgery, type of pain 
scale (objective vs. self-report), and PCA/NCA versus nurse-
administered boluses.
Efficacy–Burden Relationships
When opioids were used as the study drug, a positive rela-
tionship was found between pain in the control group and 
time to first rescue medication (β = 0.37, R2 = 0.44), a 
small relationship between pain in the control group and 
total opioid use (β = 0.16, R2 = 0.16), but no relationship 
with the percentage requiring recue medications (β = 0.06, 
R2 = 0.01) (figs. 1 and 2 in Supplemental Digital Content 
1, http://links.lww.com/ALN/B91, which depict the efficacy–
burden relationship for opioids as the study drug). Although 
time to rescue showed good assay sensitivity for opioid spar-
ing, trials using this endpoint had higher pain scores in control 
groups compared with trials using the other primary opioid-
sparing endpoints.
When NSAIDs were used as the study drug, a positive 
strong relationship was found between pain in the control 
group and time to first rescue medication (β = 0.70, R2 = 0.25), 
Fig. 6. Forest plot for local anesthetics as study drug. Expressed as Hedges’ g score and 95% CIs. Negative scores favor study 
drug over control. *Study included more than one active treatment arm.
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Fig. 7. Efficacy—burden relationship for nonsteroidal antiin-
flammatory drugs as the study drug. (A) Rescue opioid usage 
(milligram per kilogram per hour) as the outcome. (B) Percent-
age requiring rescue medication as the outcome. (C) Time to 
first rescue medication (minutes) as the outcome. Percent 
MPE = percent maximum possible effect: placebo—study/
placebo.
a small relationship between pain in the control group and 
percentage requiring recue medications (β = 0.18, R2 = 0.025), 
but no relationship with the total opioid use (β = 0.12, R2 = 0.01) 
(figs. 7 and 8).
When acetaminophen was used as the study drug, no 
relationship was found between pain in the control group 
and percentage requiring recue medications (β = 0.007, 
R2 = 0), or total opioid use (β = 0.06, R2 = 0.0001). Since 
only one study provided pain scores when looking at time 
to first rescue medication, no association could be assessed 
(figs. 3 and 4 in Supplemental Digital Content 1, http://
links.lww.com/ALN/B91, which depict the efficacy–vur-
den relationship for acetaminophen as the study drug).
When local anesthetics were used as the study drug, a 
positive relationship was found between pain in the con-
trol group and time to first rescue medication (β = 0.53, 
R2 = 0.53), percentage requiring recue medications (β = 
0.29, R2 = 0.40), and total opioid use (β = 0.29, R2 = 
0.40) (figs. 9 and 10).
Discussion
Our systematic review and quantitative analysis examined 
rescue analgesic designs in pediatric trials of four commonly 
used classes of analgesics for acute pain. We considered these 
designs from the standpoint of usefulness as a surrogate mea-
sure of analgesic efficacy and from the standpoint of burden of 
unrelieved pain in the subjects, particularly in control groups.
Opioid Sparing as a Surrogate Measure of Analgesic 
Efficacy
Although opioid sparing could be demonstrated in a high per-
centage of trials in this systematic review, the magnitude of res-
cue opioid sparing varied greatly. Some sources of variability 
in these trials appears due to: (1) the test drug (dose, bioavail-
ability, intrinsic efficacy, time course of action relative to the 
timing of measurements), (2) type of opioid-sparing endpoint 
(milligram per kilogram per hour, time to rescue, percent of 
subjects needing rescue), (3) method of analysis (Hedges’ g 
vs. percent sparing), (4) type of surgery, and (5) a range of 
additional demographic variables. Despite an initial survey 
of almost 6,000 abstracts from pediatric analgesic trials using 
nested search terms, ultimately only 85 trials fit our inclusion 
criteria for quantitative analysis. Analysis indicated great het-
erogeneity in each of the five sources of variability. Based on 
this, recommendations can be only somewhat provisional.
We evaluated the three most common reported rescue-
analgesic–sparing outcomes: (1) total dose (milligram per 
kilogram per hour), (2) percentage of children requiring res-
cue medication, and (3) time to first rescue medication (min-
utes). Variations in the design methodologies of the analgesic 
clinical trial influence the sensitivity for detecting differences 
in each of these outcomes, making it difficult to designate 
one of these outcomes as an accepted standard for all studies. 
Total dose seems to be the outcome most often chosen. This 
parameter can be used in single-dose or multiple-doses trials. 
However, this outcome is susceptible to the nonlinear inter-
actions between the study drug and the rescue medication. In 
addition, for a single-dose study drug with strong efficacy but 
short duration of action, effect size magnitudes will depend 
on the time period chosen for recording between-group dif-
ferences, and use of a long-acting rescue opioid might wash 
out between-group differences. One recent trial published 
after we completed the systematic review, used PCA via suf-
entanil as the rescue analgesic to evaluate thoracic paraverte-
bral blockade for the Nuss operation for pectus excavatum. 
This study showed excellent opioid sparing, but also had high 
pain scores in the control group.100 In future studies evalu-
ating rescue opioids with relatively short context-sensitive 
half-times, we believe that it is important to permit escala-
tion of dosing parameters in the setting of unrelieved pain. 
Time to first rescue medication appears useful in single-
dose studies (e.g., nerve blocks, infiltrations) and allows us 
to have a more clear view of the primary effect of the study 
drug. However, this parameter appears less useful for very 
short duration study drugs or multiple dose trials. Finally, 
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percentage requiring rescue medication can be useful in small 
procedures, when the pain scores and the time and amount 
of rescue medication needed are low.
Pain Scores, Burden on Control Subjects, and Ethical 
Considerations
From an ethical standpoint, it was noteworthy that, among 
the 83 studies included in this review, the mean pain scores 
in the control arm were mild or moderate (averaging 3.4 
out of 10 in a standardized scale), and only very rarely 
severe. PCA/NCA paradigms seem particularly effective for 
preventing high pain scores among children randomized to 
control groups.
Previous research indicates that, in routine clinical use, 
patients and nurses do not dose PCA or NCA, respectively, 
based solely on pain intensity, but dosing is based also on a 
range of other factors, including anticipation of future pain 
and on side-effects. In PCA/NCA trials, dosing was not titrated 
to give equal scores in the study drug and control groups, but 
rather mean pain scores were lower in the study drug arms (P 
= 0.013). Based on this, there is a potential for opioid spar-
ing alone to underestimate the analgesic effect of a study drug. 
Fig. 8. Nonsteroidal antiinflammatory drugs as the study drug. (A) Rescue opioid usage (milligram per kilogram per hour) as 
the outcome. (B) Percentage requiring rescue medication as the outcome. (C) Time to first rescue medication (minutes) as the 
outcome. Colorless circles indicate studies without pain scores.
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Fig. 9. Efficacy–burden relationship for local anesthetics 
as the study drug. (A) Rescue opioid usage (milligram per 
kilogram per hour) as the outcome. (B) Percentage requiring 
rescue medication as the outcome. (C) Time to first rescue 
medication (minutes) as the outcome. Percent MPE = percent 
maximum possible effect: placebo—study/placebo.
Future studies may consider the potential utility of composite 
efficacy measures based on both pain scores and opioid sparing.
Limitations
As with all quantitative systematic reviews, meta-analyses are 
only as good as the data that are reported and the description 
of methods in each study. Data of many studies could not be 
included due to lack of necessary information. In our meta-
analysis, we included multiple treatment arms from a single 
study. We are aware that duplicating the number of patients 
in a control group between two comparisons may generate a 
unit-of-analysis error. This could have been avoided by either 
splitting the shared group resulting in a smaller sample size 
and including two or more comparisons, by combining 
groups to create pairwise comparisons, or by undertaking a 
multiple treatment analysis. However, the goal of our study 
was not to test a specific drug’s efficacy in either the pre-
vention or treatment of pain but to see if immediate rescue 
designs are feasible and usable outcomes in both these kinds 
of studies, over various types of surgeries and intervention 
drugs, and to consider the utility of different opioid-sparing 
endpoints. It is clear that variability in study design, type of 
surgery, method of opioid delivery, duration of study drug 
administration, and reported outcome measures all impact 
on the likelihood and degree of positive findings and thus 
our quantitative results should be interpreted as exploratory.
Conclusions and Recommendations for 
Future Trials
Immediate rescue analgesic trials show reasonable assay sen-
sitivity and tolerably low burden (low-moderate pain scores) 
for children after surgery. From a clinician’s standpoint, opi-
oid sparing matters only if it is associated with meaningful 
improvements in clinical outcome measures, including pain 
scores, reductions in side-effects such as nausea, vomiting, 
itching, bowel dysfunction, etc., as well as in the time course 
of recovery, rehabilitation, and postoperative behavior. 
Acetaminophen, NSAIDs, spinal morphine, and a range of 
types of regional anesthesia are indeed effective at reducing 
systemic opioid use, but the degree of opioid sparing varies 
both with drug, dose, technique, and type of surgery.
Patient-controlled analgesia/nurse-controlled analgesia 
paradigms seem ideal for more extensive surgeries, repeated 
dosing of the study drug, or trials involving long-acting study 
drugs. Surrogate efficacy measures are important for guiding 
analgesic prescribing in infants and children, but they are not 
the only outcome measures that are essential components of 
pediatric analgesic trials. As outlined by previous consensus 
groups, including the Initiative on Methods, Measurement, and 
Pain Assessment in Clinical Trials,101 measures of safety, side-
effects, hospital stay, complications, behavioral measures, and 
functional recovery parameters are essential as well. The com-
bination of these elements will allow for ethical and feasible 
study designs in future pediatric analgesic trials.
Acknowledgments
The authors thank Paul A. Bain, Ph.D. (Countway Library of 
Medicine, Harvard University, Boston, Massachusetts), and 
Alison Clapp, M.L.I.S. (Boston Children’s Hospital, Harvard 
Medical School, Boston, Massachusetts), for their assistance 
in searching the literature, and Ted Kaptchuk, B.A. (Beth 
Israel Deaconess Medical Center, Harvard Medical School, 
Boston, Massachusetts), for providing mentoring, which 
was supported by National Institutes of Health grant no. 
2K24AT004095 (Bethesda, Maryland).
This study was supported by a grant project (P2B-
SP1_148628) awarded to Dr. Kossowsky by the Swiss Na-
tional Science Foundation (Bern, Switzerland) and by the 
Sara Page Mayo Endowment for Pediatric Pain Research, Ed-
ucation and Treatment (Boston, Massachusetts) to Dr. Berde.
Competing Interests
The authors declare no competing interests.
Correspondence
Address correspondence to Dr. Kossowsky: Department of 
Anesthesiology, Perioperative and Pain Medicine, Boston 
Anesthesiology 2015; 122:150-71 168 Kossowsky et al.
Rescue Designs for Pediatric Analgesic Trials
Children’s Hospital, 333 Longwood Avenue, Boston, Mas-
sachusetts 02446. joe.kossowsky@childrens.harvard.edu. 
Information on purchasing reprints may be found at www.
anesthesiology.org or on the masthead page at the begin-
ning of this issue. ANESTHESIoLogy’s articles are made freely 
accessible to all readers, for personal use only, 6 months 
from the cover date of the issue.
References
 1. Berde CB, Walco GA, Krane EJ, Anand KJ, Aranda JV, Craig 
KD, Dampier CD, Finkel JC, Grabois M, Johnston C, Lantos J, 
Lebel A, Maxwell LG, McGrath P, Oberlander TF, Schanberg 
LE, Stevens B, Taddio A, von Baeyer CL, Yaster M, Zempsky 
WT: Pediatric analgesic clinical trial designs, measures, 
and extrapolation: Report of an FDA scientific workshop. 
Pediatrics 2012; 129:354–64
 2. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ: When pla-
cebo controlled trials are essential and equivalence trials are 
inadequate. BMJ 1998; 317:875–80
 3. Permanand G, Mossialos E, McKee M: The EU’s new paediat-
ric medicines legislation: Serving children’s needs? Arch Dis 
Child 2007; 92:808–11
 4. Finkel JC, Finley A, Greco C, Weisman SJ, Zeltzer L: 
Transdermal fentanyl in the management of children with 
chronic severe pain: Results from an international study. 
Cancer 2005; 104:2847–57
 5. Tomlinson D, von Baeyer CL, Stinson JN, Sung L: A system-
atic review of faces scales for the self-report of pain intensity 
in children. Pediatrics 2010; 126:e1168–98
Fig. 10. Local anesthetics as the study drug. (A) Rescue opioid usage (milligram per kilogram per hour) as the outcome. 
(B) Percentage requiring rescue medication as the outcome. (C) Time to first rescue medication (minutes) as the outcome. 
Colorless circles indicate studies without pain scores.
Anesthesiology 2015; 122:150-71 169 Kossowsky et al.
PAIN MeDICINe
 6. von Baeyer CL, Spagrud LJ: Systematic review of observa-
tional (behavioral) measures of pain for children and adoles-
cents aged 3 to 18 years. Pain 2007; 127:140–50
 7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, 
Gavaghan DJ, McQuay HJ: Assessing the quality of reports of 
randomized clinical trials: Is blinding necessary? Control Clin 
Trials 1996; 17:1–12
 8. Hedges LV, Olkin I: Statistical Methods for Meta-analysis. 
New York, Academic Press, 1985
 9. Brockwell SE, Gordon IR: A comparison of statistical meth-
ods for meta-analysis. Stat Med 2001; 20:825–40
 10. Rosenthal R: Meta-analytic Procedures for Social Research. 
London, United Kingdom, Sage Publications, 1991
 11. Cochran WG: The combination of estimates from different 
experiments. Biometrics 1954; 10:101–29
 12. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring 
inconsistency in meta-analyses. BMJ 2003; 327:557–60
 13. Wong I, St John-Green C, Walker SM: Opioid-sparing effects of 
perioperative paracetamol and nonsteroidal anti-inflammatory 
drugs (NSAIDs) in children. Paediatr Anaesth 2013; 23:475–95
 14. Dewey WL, Harris LS, Howes JF, Nuite JA: The effect of vari-
ous neurohumoral modulators on the activity of morphine 
and the narcotic antagonists in the tail-flick and phenylqui-
none tests. J Pharmacol Exp Ther 1970; 175:435–42
 15. Ali SM, Shahrbano S, Ulhaq TS: Tramadol for pain relief in 
children undergoing adenotonsillectomy: A comparison with 
dextromethorphan. Laryngoscope 2008; 118:1547–9
 16. Antila H, Manner T, Kuurila K, Salanterä S, Kujala R, Aantaa 
R: Ketoprofen and tramadol for analgesia during early recov-
ery after tonsillectomy in children. Paediatr Anaesth 2006; 
16:548–53
 17. Ayatollahi V, Behdad S, Hatami M, Moshtaghiun H, 
Baghianimoghadam B: Comparison of peritonsillar infiltra-
tion effects of ketamine and tramadol on post tonsillectomy 
pain: A double-blinded randomized placebo-controlled clini-
cal trial. Croat Med J 2012; 53:155–61
 18. Batra YK, Lokesh VC, Panda NB, Rajeev S, Rao KL: Dose-
response study of intrathecal fentanyl added to bupivacaine 
in infants undergoing lower abdominal and urologic surgery. 
Paediatr Anaesth 2008; 18:613–9
 19. Bean-Lijewski JD, Hunt RD: Effect of ketorolac on bleeding 
time and postoperative pain in children: A double-blind, pla-
cebo-controlled comparison with meperidine. J Clin Anesth 
1996; 8:25–30
 20. Campbell FA, Yentis SM, Fear DW, Bissonnette B: Analgesic 
efficacy and safety of a caudal bupivacaine-fentanyl mixture 
in children. Can J Anaesth 1992; 39:661–4
 21. Dawson GS, Seidman P, Ramadan HH: Improved postopera-
tive pain control in pediatric adenotonsillectomy with dex-
tromethorphan. Laryngoscope 2001; 111:1223–6
 22. Doyle E, Robinson D, Morton NS: Comparison of patient-
controlled analgesia with and without a background infusion 
after lower abdominal surgery in children. Br J Anaesth 1993; 
71:670–3
 23. Doyle E, Harper I, Morton NS: Patient-controlled analgesia 
with low dose background infusions after lower abdominal 
surgery in children. Br J Anaesth 1993; 71:818–22
 24. Eschertzhuber S, Hohlrieder M, Keller C, Oswald E, 
Kuehbacher G, Innerhofer P: Comparison of high- and low-
dose intrathecal morphine for spinal fusion in children. Br J 
Anaesth 2008; 100:538–43
 25. Gall O, Aubineau JV, Bernière J, Desjeux L, Murat I: Analgesic 
effect of low-dose intrathecal morphine after spinal fusion in 
children. ANESTHESIoLogY 2001; 94:447–52
 26. ganesh A, Adzick NS, Foster T, Cucchiaro g: Efficacy of addi-
tion of fentanyl to epidural bupivacaine on postoperative 
analgesia after thoracotomy for lung resection in infants. 
ANESTHESIoLogY 2008; 109:890–4
 27. Hammer GB, Ramamoorthy C, Cao H, Williams GD, Boltz 
MG, Kamra K, Drover DR: Postoperative analgesia after spi-
nal blockade in infants and children undergoing cardiac sur-
gery. Anesth Analg 2005; 100:1283–8
 28. Hasan RA, Kartush JM, Thomas JD, Sigler DL: Oral dextro-
methorphan reduces perioperative analgesic administration 
in children undergoing tympanomastoid surgery. Otolaryngol 
Head Neck Surg 2004; 131:711–6
 29. Heiba MH, Atef A, Mosleh M, Mohamed R, El-Hamamsy M: 
Comparison of peritonsillar infiltration of tramadol and lido-
caine for the relief of post-tonsillectomy pain. J Laryngol 
Otol 2012; 126:1138–41
 30. Kawaraguchi Y, otomo T, ota C, Uchida N, Taniguchi A, 
Inoue S: A prospective, double-blind, randomized trial 
of caudal block using ropivacaine 0.2% with or without 
fentanyl 1 microg kg-1 in children. Br J Anaesth 2006; 
97:858–61
 31. Kim SH, Lee MH, Seo H, Lee IG, Hong JY, Hwang JH: 
Intraoperative infusion of 0.6-0.9 μg·kg(-1)·min(-1) remi-
fentanil induces acute tolerance in young children after 
laparoscopic ureteroneocystostomy. ANESTHESIoLogY 2013; 
118:337–43
 32. Krane EJ, Jacobson LE, Lynn AM, Parrot C, Tyler DC: Caudal 
morphine for postoperative analgesia in children: A com-
parison with caudal bupivacaine and intravenous morphine. 
Anesth Analg 1987; 66:647–53
 33. Lawhorn CD, Brown RE Jr: Epidural morphine with butor-
phanol in pediatric patients. J Clin Anesth 1994; 6:91–4
 34. Lawhorn CD, Stoner JM, Schmitz ML, Brown RE Jr, Stewart 
FW, Volpe P, Shirey R: Caudal epidural butorphanol plus 
bupivacaine versus bupivacaine in pediatric outpatient geni-
tourinary procedures. J Clin Anesth 1997; 9:103–8
 35. Mane RS, Sanikop CS, Dhulkhed VK, Gupta T: Comparison 
of bupivacaine alone and in combination with fentanyl or 
pethidine for bilateral infraorbital nerve block for postop-
erative analgesia in paediatric patients for cleft lip repair: A 
prospective randomized double blind study. J Anaesthesiol 
Clin Pharmacol 2011; 27:23–6
 36. McDonnell C, Zaarour C, Hull R, Thalayasingam P, Pehora 
C, Ahier J, Crawford MW: Pre-treatment with morphine does 
not prevent the development of remifentanil-induced hyper-
algesia. Can J Anaesth 2008; 55:813–8
 37. Ozcengiz D, Gunduz M, Ozbek H, Isik G: Comparison of 
caudal morphine and tramadol for postoperative pain con-
trol in children undergoing inguinal herniorrhaphy. Paediatr 
Anaesth 2001; 11:459–64
 38. Rosen KR, Rosen DA: Caudal epidural morphine for con-
trol of pain following open heart surgery in children. 
ANESTHESIoLogY 1989; 70:418–21
 39. Rose JB, Cuy R, Cohen DE, Schreiner MS: Preoperative oral 
dextromethorphan does not reduce pain or analgesic con-
sumption in children after adenotonsillectomy. Anesth Analg 
1999; 88:749–53
 40. Sharma A, Tallchief D, Blood J, Kim T, London A, Kharasch 
ED: Perioperative pharmacokinetics of methadone in adoles-
cents. ANESTHESIoLogY 2011; 115:1153–61
 41. Suominen PK, Ragg PG, McKinley DF, Frawley G, But WW, 
Eyres RL: Intrathecal morphine provides effective and safe 
analgesia in children after cardiac surgery. Acta Anaesthesiol 
Scand 2004; 48:875–82
 42. Suski M, Bujak-Gizycka B, Madej J, Kacka K, Dobrogowski J, 
Woron J, Olszanecki R, Korbut R: Co-administration of dex-
tromethorphan and morphine: Reduction of post-operative 
pain and lack of influence on morphine metabolism. Basic 
Clin Pharmacol Toxicol 2010; 107:680–4
 43. Tarkkila P, Viitanen H, Mennander S, Annila P: Comparison 
of remifentanil versus ketamine for paediatric day case ade-
noidectomy. Acta Anaesthesiol Belg 2003; 54:217–22
Anesthesiology 2015; 122:150-71 170 Kossowsky et al.
Rescue Designs for Pediatric Analgesic Trials
 44. Ugur MB, Yilmaz M, Altunkaya H, Cinar F, Ozer Y, Beder L: 
Effects of intramuscular and peritonsillar injection of trama-
dol before tonsillectomy: A double blind, randomized, pla-
cebo-controlled clinical trial. Int J Pediatr Otorhinolaryngol 
2008; 72:241–8
 45. Umuroğlu T, Eti Z, Ciftçi H, Yilmaz Göğüş F: Analgesia for 
adenotonsillectomy in children: A comparison of morphine, 
ketamine and tramadol. Paediatr Anaesth 2004; 14:568–73
 46. Viitanen H, Annila P: Analgesic efficacy of tramadol 2 mg 
kg(-1) for paediatric day-case adenoidectomy. Br J Anaesth 
2001; 86:572–5
 47. Watcha MF, Jones MB, Lagueruela RG, Schweiger C, White 
PF: Comparison of ketorolac and morphine as adjuvants dur-
ing pediatric surgery. ANESTHESIoLogY 1992; 76:368–72
 48. Adarsh E, Mane R, Sanikop C, Sagar S: Effect of pre-operative 
rectal diclofenac suppository on post-operative analgesic 
requirement in cleft palate repair: A randomised clinical trial. 
Indian J Anaesth 2012; 56:265–9
 49. Bridge HS, Montgomery CJ, Kennedy RA, Merrick PM: 
Analgesic efficacy of ketorolac 0.5% ophthalmic solution 
(Accular) in paediatric strabismus surgery. Paediatr Anaesth 
2000; 10:521–6
 50. Dawson KH, Egbert MA, Myall RW: Pain following iliac crest 
bone grafting of alveolar clefts. J Craniomaxillofac Surg 1996; 
24:151–4
 51. Kokki H, Hendolin H, Maunuksela EL, Vainio J, Nuutinen 
L: Ibuprofen in the treatment of postoperative pain in 
small children. A randomized double-blind-placebo con-
trolled parallel group study. Acta Anaesthesiol Scand 1994; 
38:467–72
 52. Kokki H, Nikanne E, Tuovinen K: I.v. intraoperative ketopro-
fen in small children during adenoidectomy: A dose-finding 
study. Br J Anaesth 1998; 81:870–4
 53. Kokki H, Homan E, Tuovinen K, Purhonen S: Perioperative 
treatment with i.v. ketoprofen reduces pain and vomiting in 
children after strabismus surgery. Acta Anaesthesiol Scand 
1999; 43:13–8
 54. Kokki H, Tuovinen K, Hendolin H: The effect of intravenous 
ketoprofen on postoperative epidural sufentanil analgesia in 
children. Anesth Analg 1999; 88:1036–41
 55. Kokki H, Tuomilehto H, Tuovinen K: Pain management after 
adenoidectomy with ketoprofen: Comparison of rectal and 
intravenous routes. Br J Anaesth 2000; 85:836–40
 56. Kokki H, Salonen A, Nikanne E: Perioperative intravenous 
ketoprofen neither prolongs operation time nor delays dis-
charge after adenoidectomy in children. Paediatr Anaesth 
2001; 11:59–64
 57. Kokki H, Salonen A: Comparison of pre- and postoperative 
administration of ketoprofen for analgesia after tonsillec-
tomy in children. Paediatr Anaesth 2002; 12:162–7
 58. Kokki H, Purhonen S, Teräsvirta M, Ylönen P: Ketoprofen 
for add-on pain treatment to paracetamol after strabismus 
surgery in children. Clin Drug Investig 2004; 24:237–44
 59. Korpela R, Silvola J, Laakso E, Meretoja OA: Oral naproxen 
but not oral paracetamol reduces the need for rescue analge-
sic after adenoidectomy in children. Acta Anaesthesiol Scand 
2007; 51:726–30
 60. Morton NS, o’Brien K: Analgesic efficacy of paracetamol and 
diclofenac in children receiving PCA morphine. Br J Anaesth 
1999; 82:715–7
 61. Munro HM, Walton SR, Malviya S, Merkel S, Voepel-Lewis T, 
Loder RT, Farley FA: Low-dose ketorolac improves analgesia 
and reduces morphine requirements following posterior spi-
nal fusion in adolescents. Can J Anaesth 2002; 49:461–6
 62. Nikanne E, Kokki H, Tuovinen K: Comparison of peri-
operative ketoprofen 2.0 mg kg-1 with 0.5 mg kg-1 i.v. in 
small children during adenoidectomy. Br J Anaesth 1997; 
79:606–8
 63. Oztekin S, Hepağuşlar H, Kar AA, Ozzeybek D, Artikaslan 
O, Elar Z: Preemptive diclofenac reduces morphine use after 
remifentanil-based anaesthesia for tonsillectomy. Paediatr 
Anaesth 2002; 12:694–9
 64. Ryhänen P, Adamski J, Puhakka K, Leppäluoto J, Vuolteenaho 
O, Ryhänen J: Postoperative pain relief in children. A com-
parison between caudal bupivacaine and intramuscular 
diclofenac sodium. Anaesthesia 1994; 49:57–61
 65. Rugyte D, Kokki H: Intravenous ketoprofen as an adjunct 
to patient-controlled analgesia morphine in adolescents with 
thoracic surgery: A placebo controlled double-blinded study. 
Eur J Pain 2007; 11:694–9
 66. Sheeran PW, Rose JB, Fazi LM, Chiavacci R, McCormick L: 
Rofecoxib administration to paediatric patients undergoing 
adenotonsillectomy. Paediatr Anaesth 2004; 14:579–83
 67. Sims C, Johnson CM, Bergesio R, Delfos SJ, Avraamides EA: 
Rectal indomethacin for analgesia after appendicectomy in 
children. Anaesth Intensive Care 1994; 22:272–5
 68. Sutters KA, Levine JD, Dibble S, Savedra M, Miaskowski C: 
Analgesic efficacy and safety of single-dose intramuscular 
ketorolac for postoperative pain management in children 
following tonsillectomy. Pain 1995; 61:145–53
 69. Sutters KA, Shaw BA, Gerardi JA, Hebert D: Comparison 
of morphine patient-controlled analgesia with and without 
ketorolac for postoperative analgesia in pediatric orthopedic 
surgery. Am J orthop (Belle Mead NJ) 1999; 28:351–8
 70. Tuomilehto H, Kokki H, Tuovinen K: Comparison of intrave-
nous and oral ketoprofen for postoperative pain after ade-
noidectomy in children. Br J Anaesth 2000; 85:224–7
 71. Tuomilehto H, Kokki H: Parenteral ketoprofen for pain man-
agement after adenoidectomy: Comparison of intravenous 
and intramuscular routes of administration. Acta Anaesthesiol 
Scand 2002; 46:184–9
 72. Vetter TR, Heiner EJ: Intravenous ketorolac as an adjuvant to 
pediatric patient-controlled analgesia with morphine. J Clin 
Anesth 1994; 6:110–3
 73. Viitanen H, Tuominen N, Vääräniemi H, Nikanne E, Annila 
P: Analgesic efficacy of rectal acetaminophen and ibuprofen 
alone or in combination for paediatric day-case adenoidec-
tomy. Br J Anaesth 2003; 91:363–7
 74. Bremerich DH, Neidhart g, Heimann K, Kessler P, Behne 
M: Prophylactically-administered rectal acetaminophen does 
not reduce postoperative opioid requirements in infants and 
small children undergoing elective cleft palate repair. Anesth 
Analg 2001; 92:907–12
 75. Dashti GA, Amini S, Zanguee E: The prophylactic effect of 
rectal acetaminophen on postoperative pain and opioid 
requirements after adenotonsillectomy in children. Middle 
East J Anesthesiol 2009; 20:245–9
 76. Gandhi R, Sunder R: Postoperative analgesic efficacy of sin-
gle high dose and low dose rectal acetaminophen in pediat-
ric ophthalmic surgery. J Anaesthesiol Clin Pharmacol 2012; 
28:460–4
 77. Hiller A, Helenius I, Nurmi E, Neuvonen PJ, Kaukonen 
M, Hartikainen T, Korpela R, Taivainen T, Meretoja OA: 
Acetaminophen improves analgesia but does not reduce opi-
oid requirement after major spine surgery in children and 
adolescents. Spine (Phila Pa 1976) 2012; 37:E1225–31
 78. Kocum AI, Sener M, Caliskan E, Bozdogan N, Micozkadioglu 
D, Yilmaz I, Aribogan A: Intravenous paracetamol and dipy-
rone for postoperative analgesia after day-case tonsillectomy 
in children: A prospective, randomized, double blind, placebo 
controlled study. Braz J Otorhinolaryngol 2013; 79:89–94
 79. Korpela R, Korvenoja P, Meretoja OA: Morphine-sparing 
effect of acetaminophen in pediatric day-case surgery. 
ANESTHESIoLogY 1999; 91:442–7
 80. Mercan A, Sayin MM, Saydam S, Ozmert S, Tiryaki T: When to 
add supplemental rectal paracetamol for postoperative anal-
gesia with caudal bupivacaine in children? A prospective, 
Anesthesiology 2015; 122:150-71 171 Kossowsky et al.
PAIN MeDICINe
double-blind, randomized study. Paediatr Anaesth 2007; 
17:547–51
 81. van der Marel CD, Peters JW, Bouwmeester NJ, Jacqz-Aigrain 
E, van den Anker JN, Tibboel D: Rectal acetaminophen does 
not reduce morphine consumption after major surgery in 
young infants. Br J Anaesth 2007; 98:372–9
 82. Carney J, Finnerty O, Rauf J, Curley G, McDonnell JG, Laffey 
JG: Ipsilateral transversus abdominis plane block provides 
effective analgesia after appendectomy in children: A ran-
domized controlled trial. Anesth Analg 2010; 111:998–1003
 83. Chaudhary V, Chauhan S, Choudhury M, Kiran U, Vasdev S, 
Talwar S: Parasternal intercostal block with ropivacaine for 
postoperative analgesia in pediatric patients undergoing car-
diac surgery: A double-blind, randomized, controlled study. J 
Cardiothorac Vasc Anesth 2012; 26:439–42
 84. Coban YK, Senoglu N, oksuz H: Effects of preoperative 
local ropivacaine infiltration on postoperative pain scores in 
infants and small children undergoing elective cleft palate 
repair. J Craniofac Surg 2008; 19:1221–4
 85. Edwards TJ, Carty SJ, Carr AS, Lambert AW: Local anaesthetic 
wound infiltration following paediatric appendicectomy: A 
randomised controlled trial: Time to stop using local anaes-
thetic wound infiltration following paediatric appendicec-
tomy? Int J Surg 2011; 9:314–7
 86. Giannoni C, White S, Enneking FK, Morey T: Ropivacaine 
with or without clonidine improves pediatric tonsillectomy 
pain. Arch otolaryngol Head Neck Surg 2001; 127:1265–70
 87. Hermansson O, George M, Wester T, Christofferson R: Local 
delivery of bupivacaine in the wound reduces opioid require-
ments after intraabdominal surgery in children. Pediatr Surg 
Int 2013; 29:451–4
 88. Inanoglu K, Ozbakis Akkurt BC, Turhanoglu S, Okuyucu S, 
Akoglu E: Intravenous ketamine and local bupivacaine infiltra-
tion are effective as part of a multimodal regime for reducing 
post-tonsillectomy pain. Med Sci Monit 2009; 15:CR539–543
 89. Jagannathan N, Sohn L, Sawardekar A, Ambrosy A, Hagerty 
J, Chin A, Barsness K, Suresh S: Unilateral groin surgery in 
children: Will the addition of an ultrasound-guided ilioin-
guinal nerve block enhance the duration of analgesia of a 
single-shot caudal block? Paediatr Anaesth 2009; 19:892–8
 90. Klamt JG, Garcia LV, Stocche RM, Meinberg AC: Epidural 
infusion of clonidine or clonidine plus ropivacaine for post-
operative analgesia in children undergoing major abdominal 
surgery. J Clin Anesth 2003; 15:510–4
 91. Kundra P, Sivashanmugam T, Ravishankar M: Effect of needle 
insertion site on ilioinguinal-iliohypogastric nerve block in 
children. Acta Anaesthesiol Scand 2006; 50:622–6
 92. Meara DJ, Livingston NR, Sittitavornwong S, Ness T, Boyce 
J, Wang D, Waite PD: Continuous infusion of bupivacaine 
for pain control after anterior iliac crest bone grafting for 
alveolar cleft repair in children. Cleft Palate Craniofac J 2011; 
48:690–4
 93. Muthukumar M, Arya VK, Mathew PJ, Sharma RK: 
Comparison of haemodynamic responses following differ-
ent concentrations of adrenaline with and without ligno-
caine for surgical field infiltration during cleft lip and cleft 
palate surgery in children. Anaesth Intensive Care 2012; 
40:114–9
 94. O’Hara JF Jr, Cywinski JB, Tetzlaff JE, Xu M, Gurd AR, 
Andrish JT: The effect of epidural vs intravenous analgesia 
for posterior spinal fusion surgery. Paediatr Anaesth 2004; 
14:1009–15
 95. Park AH, Pappas AL, Fluder E, Creech S, Lugo RA, Hotaling 
A: Effect of perioperative administration of ropivacaine 
with epinephrine on postoperative pediatric adenotonsil-
lectomy recovery. Arch otolaryngol Head Neck Surg 2004; 
130:459–64
 96. Splinter WM, Thomson ME: Somatic paravertebral block 
decreases opioid requirements in children undergoing 
appendectomy. Can J Anaesth 2010; 57:206–10
 97. Tirotta CF, Munro HM, Salvaggio J, Madril D, Felix DE, 
Rusinowski L, Tyler C, Decampli W, Hannan RL, Burke RP: 
Continuous incisional infusion of local anesthetic in pediat-
ric patients following open heart surgery. Paediatr Anaesth 
2009; 19:571–6
 98. Usmani H, Pal Singh S, Quadir A, Chana RS: A comparison 
between EMLA cream application versus lidocaine infiltra-
tion for postoperative analgesia after inguinal herniotomy in 
children. Reg Anesth Pain Med 2009; 34:106–9
 99. Joly V, Richebe P, Guignard B, Fletcher D, Maurette P, 
Sessler DI, Chauvin M: Remifentanil-induced postoperative 
hyperalgesia and its prevention with small-dose ketamine. 
ANESTHESIoLogY 2005; 103:147–55
 100. Qi J, Du B, Gurnaney H, Lu P, Zuo Y: A prospective random-
ized observer-blinded study to assess postoperative anal-
gesia provided by an ultrasound-guided bilateral thoracic 
paravertebral block for children undergoing the Nuss pro-
cedure. Reg Anesth Pain Med 2014; 39:208–13
 101. McGrath PJ, Walco GA, Turk DC, Dworkin RH, Brown MT, 
Davidson K, Eccleston C, Finley GA, Goldschneider K, 
Haverkos L, Hertz SH, Ljungman G, Palermo T, Rappaport 
BA, Rhodes T, Schechter N, Scott J, Sethna N, Svensson oK, 
Stinson J, von Baeyer CL, Walker L, Weisman S, White RE, 
Zajicek A, Zeltzer L; PedIMMPACT: Core outcome domains 
and measures for pediatric acute and chronic/recurrent pain 
clinical trials: PedIMMPACT recommendations. J Pain 2008; 
9:771–83
